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Abstract   
 The development of multiple drug resistant (MDR) behaviour in cancer poses a significant 
challenge to effective treatment, yet this is not a rare event and occurs in up to 20% of breast, lung, 
colon, and hematological malignancies. MDR is defined as the presence of clinical resistance to 
cancer therapy including resistance to medical therapies not previously used. MDR can be innate, 
or acquired over the course of treatment. The underlying causes of MDR are clearly multifactorial, 
and there are several common themes that promote the behaviour: genomic instability, impaired 
stress response pathways, and dysregulated mitosis all promote MDR behavior. These cellular 
mechanisms exist as an interrelated network of pathways, as disruption of one often impacts 
another, such as the loss of mitotic regulation promoting genomic instability. This accumulation 
of mutations may then impair the activity of various stress responses pathways, thereby reducing 
the apoptotic response to chemotherapy and promoting MDR behaviour. The Anaphase Promoting 
Complex (APC) is an evolutionarily conserved, multi-subunit E3 ubiquitin ligase enzyme that 
targets selected proteins for proteasomal degradation during mitosis and G1. Its functions include 
activation of stress response pathways and regulated progression of mitosis, which protects the 
cell from genomic instability. Previously, a correlation had been established between dysfunction 
of the APC and cancer progression, primarily indicated by the accumulation of many APC 
substrates noted in multiple cancers. Recently, this relationship was directly implicated in the 
progression of cancer into an MDR state in canine lymphomas where relapse correlated with 
impaired APC function and remission restored APC activity. Therefore, we hypothesize that 
enhancing APC activity will subsequently restore chemosensitivity in MDR cancer. 
 In yeast, novel peptides were identified that bound and activated the Saccharomyces 
cerevisiae (S. cerevisiae) APC. When stably expressed in the innately MDR breast cancer cell line 
MDA-MB-231, two of these peptides significantly enhanced APC activity. Significantly, peptide 
expression restored cytotoxic sensitivity to doxorubicin in this MDR cell population in accordance 
with relative APC activity, with greater APC activation producing greater chemosensitivity. An 
investigation of FOXO3A-dependent stress response pathways (suggested by previous studies) 
demonstrating a functional interaction between APC activity and yeast FOXO orthologs, to induce 
stress responses. We revealed FOXO3A signaling activity was increased upon APC-activating 
peptide expression, an elevation in FOXO3A activity, and therefore predicted a concurrent 
increase in stress-related apoptosis. As anticipated, peptide expression increased apoptosis with or 
without chemotherapy exposure. Peptide-dependent APC activity unexpectedly augmented 
mitotic dysregulation observed as an increased number of mitotic catastrophes, including 
chromosomal mis-segregation and micronuclei formation. The consequences of mitotic 
catastrophes are elevated genomic instability and DNA damage, which were found to be elevated. 
While this behaviour is typically considered to be tumorigenic, this phenomenon may enhance the 
cytotoxic effect of chemotherapy by inducing cell death via priming the cells with elevated 
genomic damage. Our results indicate that activation of the APC serves to enhance 
chemosensitivity in MDR cancer; however, the complicated mechanisms related to APC activity 
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Anaphase Promoting Complex activation, inhibition and substrates in cancer development and 
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substrates in the development and progression of cancer, and serves as the basis for Chapter 1, 
Introduction. I am the first author and the co-authors are Drs Troy Harkness and Terra Arnason. 
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Anaphase Promoting Complex using peptides that bind Apc10 increases resistance to stress and 
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that the development of MDR behaviour in canine lymphomas corresponds with the development 





Chapter 1. Introduction 
 
1.1 General Characteristics of Multiple Drug Resistant Behaviour  
 
 Cellular defects incurred during cancer development and progression alter the specific 
behaviours of individual malignancies. One commonly developed behaviour is multiple drug 
resistance (MDR), a phenomenon whereby the resistance to one treatment or chemotherapy 
modality results in resistance to multiple unrelated therapies that have not been previously used 
(Holohan, et al., 2013; Housman et al., 2014). Treatment resistance is a frequent occurrence, 
particularly in malignancies of the breast, prostate, hematological system and gastrointestinal 
system (Komarova 2006). A diverse array of mechanisms are known to contribute to MDR 
behaviour including impairment of stress response and apoptotic pathways (Fernald and 
Kurokawa, 2013; Miyashita and Reed, 1993), the expression of drug efflux pumps (Choi, 2005; 
Austin Doyle et al., 1998), genomic instability (Lee et al., 2011; Sansregret et al., 2018), and the 
restoration of defective DNA repair mechanisms (Bonano et al., 2014; Edwards et al, 2008; Husain 
et al., 1998). The underlying mechanisms of MDR are complex regardless of the cancer type, and 
can include some or many of these cellular changes. These pathways may be defective early on 
during cancer development, or acquired later after initial responses to treatment, and MDR 
behaviour is often described as being innate or acquired (Holohan, et al., 2013; Housman et al, 
2014). Given that each pathway itself experiences a unique series of defects to promote its aberrant 
behaviour, effective treatment of MDR behaviour poses a significant challenge (Gerlinger et al., 
2012; Vogelstein et al., 2013). Despite this, there are several commonly accepted biomarkers of 
MDR behaviour. Perhaps the most notable markers of MDR behaviour are members of the ATP-
binding cassette (ABC) transporter family which act as non-specific drug efflux pumps, the 
overexpression of which prevents the accumulation of sufficient therapeutic agent in the cell to 
induce its affects (Choi, 2005). Currently, detection of MDR responses to first line therapy result 
in a switch to rescue therapies with higher risk profiles, or in fact a change to palliative comfort 
therapy only, as there is no current effective treatment for MDR malignancy available. Emerging 
novel approaches for MDR therapy include considerations for either a combinatorial approach, or 
a synthetic lethality approach where inhibition of mechanisms complimenting the cancer 
behaviour induce cell death (Crystal et al., 2014; Liu and Tewari, 2016).  
 
1.2 Models of MDR Behaviour in Breast Cancer 
 
 Breast cancer is the most common malignancy to affect women in the world, accounting 
for 25% of all female cancers (Ghoncheh et al., 2016). Breast cancer is known to have high rates 
of treatment resistance even 20 years after initial successful responses to therapy, with rates that 
differ depending on the hormone receptors expressed on the cancer cells (Kramer et al., 2019; 
Reddy et al., 2018). Histological grading of breast cancer has identified several subtypes of breast 
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cancer. Categorizing the subtypes of breast cancer is based in part on the presence of three different 
receptors: estrogen (ER), progesterone (PR) and human epidermal growth factor receptor 2 
(HER2) (Foulkes et al., 2010). Breast cancers expressing either ER and/or PR are often treated 
with endocrine therapies to block proliferation signals arising through these receptors (including 
the treatments tamoxifen and toremifene) (Printz, 2014). Breast cancers whose development are 
driven by the overexpression of HER2 are referred to as HER2+, and similar to ER and PR positive 
cancers, are treated with therapies targeting the HER2 receptor (including trastuzumab and 
pertuzumab) (Oh and Bang, 2020). In contrast are those breast cancers that do not express any of 
the classic receptors and therefore cannot benefit from blockade in the same way and are referred 
to as triple negative breast cancer (TNBC). TNBC typically exhibits more aggressive 
characteristics than ER, PR, or HER2+ cancers, and TNBC patients have the lowest 3-year survival 
rate of the three histological grades and requires a reliance on traditional chemotherapies as 
receptor-targeted therapies are ineffective (Kramer et al., 2019). Furthermore, TNBC breast cancer 
patients experience elevated instances of resistance to chemotherapy and metastasis, resulting in 
patients who have shorter relapse-free periods and lower survival rates (D’Amato et al., 2015; 
Liedtke et al., 2008; Tan et al., 2008). Of diagnosed breast cancers, 10-17% are TNBC leaving 
few effective therapeutic options for a large population of patients (Tan et al., 2008). 
 
1.3 General Characteristics of the Anaphase Promoting Complex 
  
 The anaphase promoting complex (APC) is an evolutionarily conserved multi-subunit E3 
ubiquitin ligase (E3 Ub-ligase) enzyme named after its first recognized function, that of promoting 
the segregation of chromosomes during mitosis, thus initiating anaphase. However, the role of the 
APC in cellular behaviours has expanded greatly beyond this initial function, and the APC is now 
recognized to participate in interphase regulation (Choudhury et al., 2016; Wei et al., 2004), cell 
cycle arrest (Basserman et al., 2008; Sudo et al., 2001), and induction of stress responses (Malo et 
al., 2016; Postnikoff et al., 2012; Simpson-Lavy et al., 2009). When impaired, the APC is known 
to result in genomic instability (Engelbert et al., 2008; Greil et al., 2016; Kim et al., 2011), cell 
cycle dysregulation (Greil et al., 2016; Park et al., 2008; Sigi et al., 2009; Sudo et al., 2001) and 
diminished stress responses (Postnikoff et al., 2012; Simpson-Lavy et al., 2009; Sudo et al., 2001), 
all key aspects of cancer development and progression (Hanahan and Weinberg, 2011; Harkness, 
2018). The mammalian APC is highly related structurally and functionally to that of lower 
eukaryotes including the yeast (S. cerevisiae). In humans, the APC is composed of 14 subunits, 
with key subunits including APC2 and APC11 which are critical for the E3-ligase catalytic activity 
(Thornton et al., 2006). The CDC27 subunit, which binds to CDC20 (cell division cycle 20) and 
CDH1 (CDC20 and Fizzy homolog 1) coactivator proteins at mutually exclusive positions in the 
cell cycle (Vodermaier et al., 2003). The APC10 subunit contributes to E3 ligase activity via 
substrate recruitment to the inner cavity of the APC structure (Buschhorn et al., 2011).  
 The APC is principally regulated through the exclusive binding of one of two coactivators, 
CDC20 and CDH1, forming APCCDC20 and APCCDH1 respectively. At the initiation of mitosis, the 
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APC is inhibited through impaired association to either coactivator, then becomes active upon 
CDC20 binding (Figure 1.1). During mitotic exit CDC20 dissociates from the APC, which is then 
bound by CDH1 for the remainder of mitosis until CDH1 degradation in G1 (Sivakumar and 
Gorbsky, 2015). The availability for CDH1 and CDC20 to bind the APC is regulated through 
acetylation of both CDC20 and CDH1 and their deacetylation is a key regulatory event impacting 
APC activity, as acetylation prevents their respective bindings to the APC (Kim et al., 2011).   
 The primary recognition motif of proteins selected and targeted by the APC for degradation 
is the destruction box (D-box, RxxLxxI/VxN), which exists on a multitude of APC substrates and 
is recognized by both the APCCDC20 and APCCDH1 complexes (Glotzer et al., 1991; Pfleger and 
Kirschner, 2000). Both coactivators contain a WD40 protein-binding domain that interacts with 
the APC substrates (Kraft et al., 2005), and assists with APC and E2-ubiquitin interactions to 
promote APC E3 activity (Brown et al., 2014; Brown et al., 2015; Van Voorhis and Morgan, 
2014). A variety of secondary motifs also exist that are recognized by either APCCDH1 or APCCDC20 
exclusively including the KEN box (KENxxD) (Pfleger et al., 2000) and L box (LXEXXXN) 
(Sullivan and Morgan, 2007), which are targeted by APCCDH1, and an LR motif which is targeted 
by APCCDC20 (Sedgwick et al., 2019). These secondary motifs act to target specific proteins rather 
than as general Ub-dependent degradation motifs.   
  
1.4 Normal APC Function during Mitosis 
 
 As shown in Figure 1.1, during metaphase, the Spindle Assembly Checkpoint (SAC) is 
active, delaying mitotic progression until all sister chromatids are securely attached to the mitotic 
spindle (Sivakumar et al., 2015). The SAC is maintained by the mitotic checkpoint complex 
(MCC), a multi-subunit complex that inhibits APC activity until all kinetochores are properly 
secured to a microtubule (Monda and Cheeseman, 2018). The MCC subunit component mitotic 
arrest deficient 2 (MAD2), when associated with the kinetochore via the MAD1 subunit, binds to 
the N-terminus of CDC20, which then associates with budding uninhibited by benzimidazole 3 
(BUB3) and BUB3-related 1 (BUBR1) to form the tetrameric MCC. The MCC complex binds two 
CDC20 molecules, suggesting that MCC also interacts with CDC20 bound to APC. In the cryo-
EM structure, MCC-CDC20 binds to APCCDC20, where MCC-CDC20 occupies the large APCCDC20 
central cavity (Izawa and Pines, 2015; Yamaguchi et al., 2016). BUBR1 interacts with both 
CDC20 molecules, thereby disrupting the ability of both CDC20 molecules to bind substrate. This 
occurs because BUBR1 encodes the APC recognition motifs, D-box and KEN-box, through which 
CDC20 binds (Di Fiore et al., 2016). Once microtubules are properly attached to the kinetochores 
of chromosomes, the SAC becomes inactivated and releases CDC20 so it can in turn activate the 
APC by forming APCCDC20 (Figure 1.1, Kramer et al., 2000).  
 The inactivation of the SAC begins the first phase of APC activity whereby formation of 
the APCCDC20 complex promotes anaphase by the ubiquitination (and subsequent proteasomal 
degradation) of multiple protein targets. Two prominent proteins involved in chromosomal 
segregation are Securin (which is targeted by the APC for degradation) and Separase (which is not 
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directly targeted by the APC). Securin is an inhibitory chaperone of Separase, which acts by 
allosterically altering the conformation of bound Separase to prevent binding to target proteins 
(Luo and Tong, 2017). Separase is a cysteine protease that cleaves the kleisin subunit of cohesin. 
Cohesin acts to bind sister chromatids together and cleavage of the kleisin subunit results in 
dissolution of the cohesin ring binding sister chromosomes together, and induces chromosomal 
segregation (Lin et al., 2016; Gligoris et al., 2014). The APC drives anaphase by 
polyubiquitinating Securin, targeting it for degradation, and enabling Separase activity. The newly 
activated Separase then triggers chromosomal segregation by cleaving the kleisin subunit. While 
bound to CDC20 the APC will also self regulate in a feedback loop where it targets multiple SAC 
components to prevent further APC inhibition (Sitray-Shevan et al., 2018; Song and Rape, 2010). 
The APC will also target Cyclin B1 for degradation. Cyclin B1 functions by binding and activating 
cyclin dependent kinase 1 (CDK1) which phosphorylates multiple targets to promote mitosis, 
including several APC subunits and the second APC activator, CDH1 (Kraft et al., 2003; Kramer 
et al., 2000). The phosphorylation of APC subunits promotes APCCDC20 activity, while inhibiting 
interaction of CDH1 with the APC. Thus, the degradation of Cyclin B1 results in the loss of 
phosphorylation of CDH1, permitting its binding to the APC forming APCCDH1 (Kraft et al., 2003; 
Kramer et al., 2000).  
 The formation of APCCDH1 initiates the targeting of a new suite of protein degradation 
targets and the next phase of APC activity that permits a regulated mitotic exit. These targets 
include the proteins, CDC20, FOXM1, residual Cyclin B1, and multiple mitotic kinases including 
NIMA related 2 (NEK2A), and Aurora A/B, the degradation of which is necessary to maintain a 
regulated cell cycle (Zhang et al., 2016). The binding of CDH1 at this stage to the APC also 
triggers a negative-feedback loop where the APC simultaneously targets the CDH1 protein for 
degradation as the cells progress through G1 (Kramer et al., 2000; Visintin et al., 1997). Residual 
CDH1 will still bind the APC and the APCCDH1 complex will continue to function throughout G1 
(Castro et al., 2005). The role of the APC in regulated mitotic progression is essential for the 
maintenance of chromosomal integrity, genomic stability, and cell cycle regulation (Greil et al., 









Figure 1.1 Regulation of the APC throughout the cell cycle. Beginning in 
metaphase, the APC is inhibited through SAC binding CDC20, and CDH1 inhibitory 
phosphorylation. Upon chromosomal alignment, the SAC becomes inactive and 
CDC20 binds APC, initiating the polyubiquitination of the SAC and Cyclin B1. The 
loss of Cyclin B1 permits CDH1 replacing CDC20 during mitotic exit, inducing 
CDC20 polyubiquitination. The APC remains bound to CDH1 during G1, however 
acting in a negative-feedback loop whereby it degrades CDH1. Residual CDH1 is 
phosphorylated by Cyclin B1. The APC remains inactive from S phase until 









1.5 APC Regulation by the Mutually Exclusive Coactivators, CDC20 and CDH1 
 
1.5.1 CDC20 and APC regulation  
 CDC20 has been identified as being an oncogene, and both overexpression and augmented 
protein abundance have been correlated with poor prognosis for several unrelated cancer types 
including brain astrocytoma (Ding et al., 2017), gastric (Ding et al., 2014), breast (Karra et 
al.,2014), colorectal (Wu et al., 2013), prostate (Mao et al., 2016), and pancreatic cancers (Chang 
et al., 2012). Increased CDC20 abundance drives a dysregulated mitotic cycle by overwhelming 
the inhibitory capacity of the SAC, forcibly activating the APC despite an active SAC, and 
inducing mitotic slippage (the improper progression of mitosis despite continual SAC activity) 
(Bonaiuti et al, 2018; Pan and Chen, 2004). Overexpression of CDC20 is one mechanism that 
could lead to accumulation of CDC20 protein (Bonaiuti et al, 2018), as would its failure to be 
degraded efficiently by the proteasome in a Ub-dependent manner. One obvious mechanism would 
be the dysfunction of the APC E3-ligase activity itself through altered post-transcriptional 
modifications or impaired subunit expression, resulting in inefficient CDC20 degradation. It is 
thought that by driving improper APC activity (and therefore mitosis) that CDC20 primarily 
contributes to tumorigenesis. However, the observation that overexpression of CDC20 is 
accompanied by the overexpression of a host of other genes associated with APC impairment in 
other cancers (Zhang et al, 2019), including overexpression of other APC substrates, indicates that 
it may be APC impairment, not specifically CDC20 overexpression, that is important for cancer 
development, in at least some cases.  
 
1.5.2 CDH1 and APC regulation  
 The potential role that CDH1 plays in cancer development and progression is more 
complicated than CDC20, as it has been demonstrated to possess both tumor suppressor and 
oncogenic functions (Ishizawa et al, 2017). The generation of heterozygous CDH1+/- mice are 
haploinsufficient and incur elevated rates of cancer formation indicating an overall tumor 
suppressive function (Garcí-Higuera et al., 2008; Ishizawa et al, 2017). Loss of CDH1 activity is 
also connected with increased rates of chromosomal abnormalities (Engelbert et al., 2008; Garcí-
Higuera et al., 2008; Greil et al., 2016), elevated sensitivity to DNA damage (de Boer et al., 2016; 
Ishizawa et al, 2011; Ishizawa et al, 2017), insufficient loading of Mini-Chromosome Maintenance 
proteins (MCMs) (Greil et al., 2016), and premature S phase entry (Choudhury et al., 2016; Greil 
et al., 2016; Sigi et al., 2009; Wei et al., 2004). These abnormalities result from the loss of key 
regulatory functions of CDH1, which includes cell cycle arrest upon nutrient and genotoxic stress 
(defined as stressors on the cell that induce genetic damage) (Basserman et al., 2008; Gao et al., 
2009, Petersen et al., 2000; Simpson-Lavy et al., 2009; Sudo et al., 2001), regulation of S phase 
entrance (Choudhury et al., 2016; Park et al., 2008; Wei et al., 2004), and promoting mitotic exit 
(Hatano et al., 2016; Wäsch et al., 2002).  
 The complicated relationship between CDH1 and cancer behavior has been experimentally 
elucidated by CDH1 silencing in a B-cell acute leukemia model. Initially, CDH1 impairment 
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promoted DNA damage induced-apoptosis, however long-term inhibition resulted in the 
development of resistance to radiation-based therapy (Ishizawa et al., 2017). Furthermore, in B-
cell acute leukemia patients, CDH1 deficiency predicted a prolonged remission period, and 
elevated life expectancy (Ishizawa et al., 2017). The CDH1 protein has also been found to be 
elevated in malignant as compared to normal tissue controls (Lehman et al., 2007). The oncogenic 
behaviour of CDH1 is primarily a result of its antagonism to the SAC and can act to induce mitotic 
slippage (Nagai and Ushimaru, 2014; Park et al., 2018; Toda et al., 2012). APCCDH1 overactivity 
from either CDH1 overexpression, or loss of the APCCDH1 inhibitor, early mitotic inhibitor 1 
(EMI1), may also result in DNA re-replication through the over-degradation of Geminin (Sørensen 
et al., 2000; Yuichi et al., 2007). In G2 and S phase, Geminin acts to inhibit CDT1, which is 
responsible for initiating DNA replication. Therefore, inappropriate loss of CDT1 inhibition may 
result in DNA re-replication and induce gene duplication and aneuploidy (Machida and Dutta, 
2007; Sørensen et al., 2000; Wohlschlegel et al., 2000). The wide variety of CDH1-associated 
activities demonstrates its complicated role in cancer progression, and warrants further 
investigation. Through the cellular behaviours, the overaccumulation of CDH1 may also contribute 
to MDR behaviour through generation of genomic instability and mitotic slippage. 
 
1.6 Role of Genomic Instability in Cancer Development and MDR Behaviour 
  
1.6.1 DNA damage response pathways  
 Genomic instability refers to the accrual of genomic damage incurred through 
chromosomal instability and nucleotide instability (Giam and Rancati 2015; Sansregret et al., 
2018; Tubbs, 2017). Chromosomal instability involves the partial or entire addition and deletion 
of chromosomes, while nucleotide instability refers to mutations of individual nucleotide residues 
and DNA breaks (Giam and Rancati 2015).  One common factor promoting genomic instability is 
the impairment of the DNA damage response (DDR) pathways. Germline mutations of DNA repair 
genes including BCRA1, BRCA2, MLH1, and MSH2 are established to predispose transformation 
into a variety of cancer types, as the cells experience a reduced capacity to repair the normal 
stochastic accrual of DNA damage (Bouwmen and Jonkers, 2012; Leach et al., 1993; Moynahan 
et al., 1999; Papadopoulos et al., 1994; Wooster et al., 1995). DDR pathways may also be impaired 
through the inhibition of DNA damage sensors, such as the key regulatory proteins, p53 (Ohashi 
et al., 2015), ataxia-telangiectasia mutated (ATM, Guo et al., 2002), ataxia telangiectasia and Rad3 
related (ATR, Göhler et al., 2011), Chk1/2 (Sørensen et al., 2005; Sun et al., 2014). Malignancies 
are commonly found to contain these loss-of-function mutations, or otherwise experience impaired 
activity/expression of these sensing proteins (Yazinski and Zhu, 2016). DDR pathway defects 
prevent the recognition of DNA damage and the normal initiation of either repair or apoptosis 
(Göhler et al., 2011; Guo et al., 2002; Ohashi et al., 2015; Yazinski and Zhu, 2016), increasing the 
likelihood of acquiring de novo mutations in surviving malignant cells that trigger further cancer 
development and progression. The impairment of one DDR pathway results in oncogene addiction, 
where the proper functioning of a secondary pathway is essential for survival in the cell. This 
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phenomenon is exemplified when homologous repair pathways are inhibited through loss-of 
function BRCA2 mutations, preventing the repair of double strand breaks (Mateo et al., 2015). 
This induces reliance on repair single strand break DDR pathways to substitute the loss of double-
strand repair normally performed by homologous repair pathways. Pharmacological inhibition of 
base excision repair (BER) pathways, which are crucial for single-strand break repair, in BRCA2 
defective cells through poly(ADP–ribose) polymerase (PAPR) inhibitors results in reduced 
cellular viability and cell death (Ashworth, 2008). 
 In contrast to cellular mechanisms designed to detect DNA damage, cancer behavior can 
also change due to the altered activity of various DNA repair mechanisms, and specifically 
contribute to MDR behaviour. This occurs through an increase in DNA repair reducing the 
accumulation of DNA damage. This prevents the accrual of lethal DNA damage through chemo- 
and radio-therapy, resulting in MDR behaviour (Edwards et al, 2008; Husain et al., 1998; Kwon 
et al., 2007; Kirschner and Melton, 2010; Sakai et al., 2008). This phenomenon has been observed 
through the elevated expression of ERCC1 (excision repair cross complementing), a key 
component of nucleotide excision, recombination, double strand break, and interstrand crosslink 
repair pathways, inhibits the apoptotic response to chemotherapy and promotes drug resistance 
(Kwon et al., 2007; Kirschner and Melton, 2010). A similar phenomenon has been documented 
with BRCA1 overexpression inhibiting the response to cisplatin. However, the effect on 
chemosensitivity is dependent on the chemotherapy class used, as BRCA1 overexpression 
simultaneously promotes the sensitivity to taxanes (Husain et al., 1998). Lastly, another alteration 
causing increased DDR activity may also arise through gain of function mutations. As noted in 
BRCA2, an intragenic deletion restores defective BRCA2 activity and promotes resistance to 
cisplatin (Sakai et al., 2008; Edwards et al, 2008).  
 The role of DDR pathways in promoting MDR behaviour has led to investigations of DDR 
inhibitors to restore chemosensitivity and promote cellular apoptosis. Often cancer cells will 
become reliant on the activity of one specific DDR pathway, leading to targeting DDR pathways 
through a synthetic lethal approach. As mentioned previously, BRCA 1/2-impaired cancers 
typically rely on PARP activity to compensate for the impaired homologous repair pathways 
within the cell, yet treatment of these BRCA-impaired cancers with PARP inhibitors has 
demonstrated effective anti-tumorigenic effects (Ashworth, 2008; Farmer et al., 2005, Mateo et 
al., 2015). Furthermore, utilizing chemotherapy cocktails and therapies, such as pairing a 
chemotherapeutic with a DDR inhibitor, has been demonstrated to provoke sufficient DNA 
damage to efficiently trigger cell death (Bonano et al, 2014; Crystal et al., 2014; Selvakumaran et 
al, 2003).  
 
1.6.2 Chromosomal instability and aneuploidy  
 Chromosomal instability refers to errors relating to chromosome structure, number, and 
fragmentation (Giam and Rancati, 2015; Sansregret et al., 2018). Multiple mechanisms contribute 
to chromosomal instability including dysregulated/error prone mitosis and replication stresses 
(Burrell et al., 2013; Comailis et al., 2016; Crasta et al., 2012; Ohashi et al., 2015). Mitotic errors 
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may result in improper chromosomal segregation of a portion or entire chromosomes, generating 
aneuploidy and creating severe chromosomal damage in the daughter cells (Comailis et al., 2016; 
Crasta et al., 2012; Ohashi et al., 2015). The relationship between chromosomal instability and 
mitosis will be further discussed in section 1.7. Polyploidy similarly arises from an error in mitosis, 
occurring when the cell fails to undergo cytokinesis, and instead directly enters interphase from 
prophase or metaphase (Ohashi et al., 2015). The presence of chromosomal instability provides a 
significant source of the heterogeneity and genomic instability within the genomes of the cancer 
cell population, through induction of gene amplification, or haploinsufficiency of key oncogenes 
and tumor suppressors, thus driving tumor progression (Gerlinger et al., 2012; Lee et al, 2011).  
 In a healthy cell, the genotoxic and proteotoxic (stresses incurred in the cell resulting in 
aberrant protein regulation) stresses induced by chromosomal instability would either induce 
apoptosis, or otherwise trigger cell death. To avoid this cellular death, cancer cells frequently 
develop mutations to compensate for the severe genotoxic and proteotoxic stresses induced by 
genomic instability. Key mutations identified in yeast are the loss of function mutations to the de-
ubiquitinases, Ubp3 or Ubp6, indicating promotion of proteasomal degradation acts to protect 
cancer cells from proteotoxic stresses and promotes cell survival (Dodgson et al., 2016; Torres et 
al., 2010). There does, however, remain a point where chromosomal instability passes a tolerable 
level and the cell will experience death (Birkbak et al., 2011). Frequently this occurs during mitotic 
catastrophes. Currently there is not a universally accepted definition of mitotic catastrophe, and 
there is debate as to whether cell death necessarily be included, especially in the case of malignant 
cells. Therefore, we will define mitotic catastrophes as errors in mitosis that would induce death 
in a healthy cell. Aside from errors during mitosis (lagging chromosomes, failure of chromosomes 
to align along a metaphase plate etc.) characteristic cellular morphologies of mitotic catastrophes 
post-mitosis are micronuclei (extranuclear chromosomes), multi-nuclei formation, and asymmetric 
nuclei formation (Caruso et al., 2011).  
 
1.6.3 Adaptational advantage of genomic instability in malignancy  
 Each cancer cell in the population experiences a unique combination of chromosomal and 
genetic defects, producing a heterogenous genome of the cell population (Gerlinger et al., 2012). 
These defects may include loss of function mutations in key tumor suppressor genes, or 
overexpression of oncogenes through gene amplification induced by aneuploidy. It is through 
accumulations of a unique series of defects within individual cancer cells that genomic instability 
provides an adaptational advantage driving numerous cancer behaviours including MDR, 
metastasis, apoptosis suppression, and heightened cell proliferation (Chen et al., 2012 Lee et al, 
2011; Yates et al., 2017). This heterogeneity in particular poses a challenge for targeted therapies 
whose anti-tumorigenic effect occurs from focusing on specific proteins that may be up or 






1.7 The Promotion of MDR Behaviour through Dysregulated Mitosis 
 
1.7.1 Mechanisms promoting dysregulated mitosis  
 One of the most common causes of a dysregulated mitosis is through the process of mitotic 
slippage. Mitotic slippage refers to processes by which chromosomal segregation occurs despite 
mitotic arrest appropriately induced by sustained SAC activity (Wäsch, 2011). Mitotic slippage is 
achieved through the premature activation of APC despite sustained active SAC repression. This 
can be accomplished through the overexpression of CDC20, as excess protein abundance prevents 
the SAC from inhibiting APC activity due to an inability to sufficiently sequester the excess 
CDC20 protein. This allows the free CDC20 to form APCCDC20 and promote anaphase, with mitotic 
slippage occurring as a result (Bonaiuti et al, 2018; Pan and Chen, 2004). A second mechanism 
whereby the APC may overcome SAC inhibition is through premature CDH1 activity. As the SAC 
does not directly inhibit CDH1 activity, failure of the regulatory mechanisms that inhibit APC 
activation via CDH1 results in mitotic slippage, as APCCDH1 can prematurely target Securin for 
degradation (Nagai et al., 2014; Park et al., 2018; Toda et al., 2012). This occurs principally if 
Cyclin B1 activity is impeded, as CDK1Cyclin B1 phosphorylation of CDH1 prohibits CDH1 from 
binding the APC. This dysfunction may occur if there is insufficient Cyclin B1 expressed during 
mitosis, or if there is a deficiency of ATP which is necessary for CDK1 to perform its inhibitory 
phosphorylation of CDH1 (Park et al., 2018). Together, then, lowering the CDC20 and Cdh1 
abundance should mitigate mitotic slippage. This could be accomplished by enhancing Ub-
mediated degradation of these APC subunits through APC activation. 
 Mitotic dysregulation may also arise from the aberrant overexpression of mitotic kinases, 
including NEK2A, polo-like kinase 1 (PLK1) and Aurora A/B, which has been linked with cancer 
development and progression (Pérez de Castro et al., 2007). This is due to their roles in regulation 
of key aspects of mitosis including, mitotic arrest, spindle assembly, and chromosome separation. 
For instance, NEK2A promotes centrosome maturation and chromosome condensation. However, 
in cancer cells, the overexpression of NEK2A dysregulates mitosis through inducing centrosome 
amplification, the generation of mitotic spindle defects, and premature centriole splitting. These 
defects may result in multi-nucleation and chromosomal mis-segregation during mitosis (Xia et 
al., 2015). Overactive NEK2A may also activate the SAC component MAD2 to induce mitotic 
arrest. This arrest is not always beneficial for cellular health however, and can induce aneuploidy 
if performed aberrantly (Liu et al., 2010). These mitotic kinases are also APC degradation 
substrates, again highlighting the possibility of therapeutic APC-activation in having a benefit on 
mitotic fidelity by normalizing the amount of these mitotic kinases. 
  
1.7.2. Mechanism through which dysregulated mitosis promotes MDR behaviour  
 While mitotic dysregulation may occur through either mitotic slippage or aberrant kinase 
activity, the consequences are similar; the presence of mitotic dysregulation impacts multiple 
aspects of cancer behaviour. The most prominent consequence of mitotic dysregulation is the 
dysregulated proliferation of cells, a characteristic behaviour of malignancies (Riffell et al., 2009). 
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The prolonged mitotic arrest prior to cells experiencing mitotic slippage induces DNA damage, 
and the resolution of mitotic arrest through slippage instead of apoptosis carries this elevated DNA 
and chromosomal damage into the daughter cells (Dalton et al., 2007; Quignon et al., 2007). 
Mitotic dysregulation may induce chromosomal mis-segregation which may result in aneuploidy 
or micronuclei formation (Crasta et al., 2012, Ohashi et al; 2015, Zhu et al., 2014). Mitotic 
slippage also produces an innate resistance to microtubule poisons. This is due to microtubule 
poisons preventing the proper formation of mitotic spindles, therefore deriving their therapeutic 
effects through inducing a prolonged mitotic arrest to trigger apoptosis. However, the 
circumvention of SAC activity prevents this outcome, therefore microtubule poisons are unable to 
induce apoptosis (Anand et al., 2003; Jiang et al., 2003; Sudo et al., 2004; Zhu et al., 2014). 
  
1.7.3. In vitro and in vivo APC targets as possible cancer therapies  
 Due to the importance of mitosis in cancer development and progression, multiple stages 
of mitosis have been carefully investigated for therapeutic potential (Huang et al., 2009; Liu et al., 
2019). Many early chemotherapy treatments were microtubule poisons and function as described 
above. Microtubule poisons are divided into two categories, microtubule stabilizers (taxol and 
docetaxel) and microtubule stabilizers (vinblastine and vindesine) and are a staple treatment across 
a variety of cancer forms (Dominguez-Braur et al., 2015) Cancers often develop resistance to these 
microtubule poisons (Jiang 2011, Huang 2009). This has led to the development of direct APC 
inhibitors (mimicking SAC activity without requiring its presence) to induce mitotic arrest and 
directly prevent slippage. Pharmacological agents include APC inhibitor (Apcin) and pro-Tosyl-
L-Arginine Methyl Ester (pro-TAME) both of which inhibit the CDC20-APC interaction, 
preventing the formation of APCCDC20 and thereby inhibiting APC activity (Sackton et al., 2014; 
Zeng et al., 2010). Pro-TAME also inhibits the second APC coactivator, CDH1, from binding the 
APC and effectively eliminates APC activity (Zeng et al., 2010). Both agents have demonstrated 
antitumorigenic results in vitro (Gao et al., 2018; Sackton et al., 2014), although due to the essential 
functions of the APC in healthy cells, in vivo toxicity is a concern (Zhang et al., 2014).  
 APC activators have also been commercially developed. Opposing mitotic arrest as a 
therapeutic route, therapies have also been developed that induce mitotic slippage through 
inhibiting SAC activity. Pharmacological agents have been developed to target the TTK and 
MAD2 subunits of the SAC, referred to as TTK inhibitors (TTKi, Wang et al., 2019) and MAD2 
inhibitor 1 (M2I-1, Kastl et al., 2015) respectively. TTKi and M2I-1 treatments derive their 
therapeutic effect from preventing the sequestration of CDC20 by the SAC (thereby increasing the 
availability of CDC20 for APC binding and activation), driving a dysregulated mitosis. This, in 
effect, induces mitotic slippage to promote catastrophic chromosomal mis-segregation and 
genomic instability, inducing cell death through mitotic catastrophes (Kastl et al., 2015; Li et al., 
2019; Maia et al., 2018; Thu et al., 2018; Wengner et al., 2016). In vitro M2I-1 and TTKi have 
demonstrated anti-tumorigenic effects both individually and when complemented with 
microtubule treatments, with several TTKi treatments currently under clinical trials in vivo (Maia 
et al., 2018; Thu et al., 2018; Wengner et al., 2016). Targeted therapies for mitotic kinases 
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frequently found to be overexpressed in cancer including NEK2A, PLK1, and Aurora A/B have 
been developed, with some agents moving into clinical trials (Gutteridge et al., 2016; Liu et al., 
2019; Tsuda et al., 2017; Xia et al., 2015). 
  
1.8 Stress Response and Apoptotic Pathways 
 
1.8.1 Suppression of apoptosis to promote MDR behaviour  
 An essential aspect in cancer cell biology is the avoidance of cell death mechanisms 
(Hanahan and Weinberg, 2011). To achieve this, malignancies often directly suppress apoptotic 
pathways through altered regulation of apoptosis signalling genes including the B-cell lymphoma 
(Bcl) family of proteins (Adams and Cory, 2007) and the Caspases (Olsson and Zhivotovsky, 
2011). This protects the cancer cell from cell death despite the presence of severe cellular defects 
that would typically result in apoptosis. Impairing apoptosis to permit cell survival also prevents 
chemotherapy from effectively inducing apoptosis, impeding its therapeutic efficacy, and 
promoting MDR behaviour. The restoration of apoptotic pathways reverses this phenomenon, and 
restores chemosensitivity (Adams and Cory, 2007; Friedrich et al., 2001; Miyashita and Reed, 
1993).  
 
1.8.2 Regulation of apoptotic pathways through stress response networks  
 Cancer may also inhibit apoptosis indirectly through the suppression of stress response 
pathways, which normally play a critical role in the powerful promotion of apoptotic processes 
(Gardai et al., 2004; Kinoshita et al., 1997; Thayyullathil et al., 2011). The activity of stress 
response pathways is intrinsically linked to proliferative pathways, with the promotion of stress 
responses impeding proliferative pathways and vice versa (Landau et al., 2012). In cancer, 
proliferative pathways often experience enhanced activity promoted by growth factor signaling, 
via prominent signaling pathways including insulin/insulin-like growth factor (IGF) and epidermal 
growth factor (EGF), often silencing stress responses (Pros et al., 2013). Cancer cells also alter 
intracellular signaling to promote growth. These signalling pathways respond to direct energy and 
nutrient sensing within the cell performed primarily (but not exclusively) by 5’ AMP-activated 
kinase (AMPK) and mammalian target of rapamycin (mTOR) complex 1 (MTORC 1) 
(DeBerardinis et al., 2008; Tokunaga et al., 2004). Impairment of stress response pathways, 
particularly through activity of the PI3K signaling pathways has been demonstrated to promote 
MDR behaviour (Goler-Baron et al., 2012; Miller et al., 2011; Tokunaga et al., 2006; Zhou et al., 
2013). 
 
1.8.3 PI3K signaling pathway and stress responses  
 Phosphoinositide 3-kinases (PI3K) signaling is regulated through growth factor signaling 
including IGF, EGF, and platelet derived growth factor (PGDF) signaling. Receptor activation 
upon binding of their respective ligands induces autophosphorylation of PI3K proteins to promote 
their activity (Singh et al., 2016). A primary function of PI3Ks is the phosphorylation of 
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phosphatidylinositol 4,5-bisphosphate (PIP2) to form phosphatidylinositol (3,4,5)-trisphosphate 
(PIP3). PIP3 induces the localization of proteins containing a pleckstrin-homology (PH) domain to 
the cell membrane where they become active through a complex series of interactions 
(Bartholomeusz et al., 2012). Prominent proteins directly activated through PI3K signaling are 
mTORC2 (regulatorily and functionally distinct from mTORC1, but share mTOR as the kinase 
domain), AKT, and 3-phosphoinositide-dependent protein kinase-1 (PDK1) (Bartholomeusz et al., 
2012). Proteins activated by PI3K signaling then proceed to promote proliferation and impair stress 
responses and apoptosis. This pathway is directly impaired by the tumor suppressor, PTEN 
(Phosphatase and tensin homolog) which dephosphorylates PIP3 into PIP2, preventing protein 
localization to the membrane and silencing PI3K signaling (Roy et al., 2010). Sustained PI3K 
signalling is a key promoter of proliferation in cancer (Foukas et al., 2010; Zhao et al., 2006).  
  
1.8.4 AKT signaling and stress responses  
 After localization to the membrane, AKT receives activating phosphorylation from PDK1 
and mTORC2 (Sarbassov et al., 2005). AKT acts as a regulator for numerous pathways including 
nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), apoptosis, and Forkhead 
Box O (FOXO) (Brunet et al., 1999; Datta et al., 1997; Jablonski et al., 2015). The net affect of 
AKT activity is the suppression of apoptosis, and promotion of the cell cycle (Datta et al., 1997; 
Xiao et al., 2010). The FOXO protein family is a group of transcription factors that promote stress 
responses by transcribing proteins to inhibit cell cycle progressing and induce apoptosis. Proteins 
transcribed by the FOXO family include Death Receptor 4/5, p27Kip1, Bim, and Bcl-6 (Greer and 
Brunet, 2005; Roy et al., 2010; Shoeb et al., 2013). AKT1 is inhibited by protein phosphatase 1 
and 2 (PPP1, PPP2), and PH domain and Leucine rich repeat Protein Phosphatases (PHLPPs) 
which dephosphorylates the activating phosphorylating events to impair AKT activity (Xiao et al., 
2010). Besides inducing MDR behaviour through the suppression of apoptotic mechanisms, AKT 
interacts with the ABC transporter family, promoting the transport vesicles containing BCRP (an 
ABC family member) to the cell membrane (Goler-Baron et al., 2012), and is correlated with 
elevated abundance of other members of the ABC family including multidrug resistance protein 1 
(MDR1), and multidrug resistance-associated protein 1 (MRP1) (Zhou et al., 2013). The activity 
of AKT promotes MDR behaviour (Miller et al., 2011; Tokunga et al., 2006), and inhibition of 
AKT in cancer has been demonstrated to induce apoptosis and enhance sensitivity to 
chemotherapy, with many of the observed affects a result of upregulated FOXO3A activity (Cleary 
et al., 2010; Roy et al., 2010; Shoeb et al., 2013). 
 
1.8.5 Cell cycle checkpoints and stress responses 
 Cell cycle regulation is dependent on the proper functioning of cell cycle checkpoints to 
arrest cell cycle progression to address proteotoxic, nutrient, and genomic stresses. Cancer 
progression induces heavy stressors on the cell, and therefore cancer cells often experience 
downregulation of cell cycle checkpoints to permit (inappropriate) cell cycle progression (An et 
al., 2015; Zhang et al., 2014). Adequate checkpoint activity is necessary for the initiation of 
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multiple DNA repair mechanisms, and loss of checkpoint activity significantly increases the 
cellular stress as the burden of damage accumulates (Göhler et al., 2011; Sørensen et al., 2005). 
Commonly, loss-of-function mutations in key cell cycle checkpoint proteins prevent the cell cycle 
arrest, and not unexpectedly are also involved in cancer development (Malumbres and Barbacid 
2009; Tutt and Ashworth 2002). Cell cycle checkpoints can be overridden through the 
overexpression of antagonistic proteins, as demonstrated by the overexpression of Aurora A that 
suppresses the normal expression of p53, BRCA 1/2, ATR, Chk 1 and RAD51, thereby indirectly 
preventing cell cycle arrest (Sun et al., 2014). Similarly, the overexpression of microRNAs also 
inhibit the expression of crucial checkpoint proteins (An et al., 2015, Zhang et al., 2014).  
 As cancer progresses into an MDR state, reactivation of cell checkpoints may contribute 
to MDR behaviour. An indicative phenotype of this behaviour is a reduction in the proliferative 
rate of cancer cells, as restored checkpoints slows cell cycle progression. A reduced proliferative 
rate has demonstrated an ability to protect cancer cells from both chemo- and radio-therapy as well 
as intrinsic cell death mechanisms (Harrington et al., 1994; Giancotti 2013). This reduced 
proliferative rate is often a result of checkpoint re-activation as it reduces the load of genotoxic 
and proteotoxic stresses in the cell likely by permitting partial genome repair and avoidance of 
cellular death, thereby promoting MDR behaviour (Ferrao et al., 2012; Morgan et al., 2010). This 
role of checkpoints in initiating DNA repair has resulted in them being targeted for inhibition as 
an anti-cancer approach. Pharmacological inhibition of Chk1 has demonstrated efficacy, both in 
vitro and in vivo, in preventing homologous repair pathways in cancer cells and enhancing the 
cytotoxic response to radiotherapy through impairment of activation of the G2 checkpoint (Ferrao 
et al., 2012; Morgan et al., 2010).  
  
1.8.6 Normal APC function and induction of cell cycle arrest 
 The APCCDH1 complex can initiate cell cycle arrest at multiple stages of the cell cycle. At 
the G2/M transition, APCCDH1 acts in conjunction with CDC14B and PLK1 to prevent progression 
into mitosis in the event of DNA damage. During the G2/M transition arrest, the phosphatase 
CDC14B will translocate to the nucleoplasm from the nucleolus and activate APCCDH1 via 
dephosphorylation of the CDH1-inhibitory phosphorylation events blocking its recruitment to the 
APC (Basserman et al. 2008). APCCDH1 will then target PLK1 for degradation preventing the 
phosphorylation of Claspin (which initiates DNA repair pathways) by PLK1. This phosphorylation 
event results in protein instability, therefore APCCDH1 activity serves to protect Claspin and 
promote DNA repair (Bassermann et al., 2008, Sudo et al., 2001).  
 The APC may also induce cell cycle arrest in response to nutrient stresses (Sudo et al., 
2001; Simpson-Lavy et al., 2009; Wirth et al., 2004). This interaction has been studied utilizing 
rapamycin, a pharmacological inhibitor of the nutrient signalling kinase, mTOR. Therefore, 
rapamycin serves as a pharmacological mimetic to nutrient stresses. When tested in in vitro CDH1-
/- chicken cell lines (DT40), rapamycin is unable to induce G1 cell cycle arrest (Sudo et al., 2001). 
This is a result of altered CDK2 and retinoblastoma (Rb) pathway signaling. Upon rapamycin 
treatment, wild type cells lose Rb phosphorylation, allowing the induction of G1 arrest, but in 
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CDH1-/- cells, Rb phosphorylation is maintained with continued cell cycle progression (Sudo et 
al., 2001). In S. cerevisiae Cdh1 has been demonstrated to protect the cell from ethanol, caffeine, 
and hyperosmotic stress, as yeast cells lacking CDH1 still progress through the cell cycle, but are 
sensitive to multiple stresses (Simpson-Lavy et al., 2009). The stress sensitivity appears to be due 
to elevated stability of Clb2 (ortholog to human Cyclin B2) and Hsl1 (ortholog of human NIM1-
related Kinase) from a partially impaired APC E3-ligase activity that fails to fully degrade these 
targets, and which in turn continues to drive cells through the G2/M transition despite the incurred 
cellular damage. Inhibition of the APC in quiescent cells drives their return to the cell cycle 
(Cappell et al., 2016; Wirth et al., 2004). This indicates that APC activity is required both for 
entrance to, and maintenance of, cell cycle arrest. 
 Studies in S. cerevisiae have revealed the complicated networks that the deacetylation 
enzyme Sir2 (the yeast orthologue of SIRT2) influences. Sir2 is an important stress response 
protein in S. cerevisiae, and it is tightly connected with a stress response network that interacts 
with the Forkhead Box transcription factors (Fkh), Fkh1 and Fkh2 (orthologues to mammalian 
FOXO proteins) (Linke et al., 2013). In S. cerevisiae, under stress conditions, the APC and Fkhs 
work together to induce a response to stress (Malo et al., 2016; Postnikoff et al., 2012). 
Furthermore, when stress is encountered, Sir2 is recruited to Clb2 promoters in a Fkh1-dependent 
manner to repress Clb2 expression and stall the cell cycle (Linke et al., 2013).  
 
1.9 Investigating the role of the APC in cancer progression and MDR behaviour  
 
 Previous studies have indicated that the APC becomes dysfunctional as cancer develops 
and this correlates with more aggressive tumor behaviours (Arnason unpublished; Lehman et al., 
2007; Wang et al., 2003; Wild al., 2018). During the progression from benign into malignant 
tumors it is common to observe an elevated abundance of APC substrates including the 
coactivators CDH1 and CDC20. This also coincides with an elevated abundance of the APC 
inhibitor early mitotic inhibitor 1 (EMI1), indicating APC activity is likely impaired during cancer 
development, as the APC is incapable of sufficiently degrading its target proteins. The impairment 
of APC activity has also been observed in canine lymphoma as the malignancy progresses from 
chemoresponsive tumors into a treatment resistant/MDR malignancy in vivo (Arnason, 
unpublished). Therefore, impaired APC activity correlates with cancer progression, particularly 
into MDR behaviour; however, a direct causal relationship has yet to be established between APC 
dysfunction and cancer progression. Therefore, in Chapter 4 we will modulate the activity of the 
APC to examine the impact of APC activity on MDR behaviour and restoring chemosensitivity. 
 Current methods of altering APC activity are based on either promoting (TTKi, M2I-1) or 
inhibiting (Apcin, pro-TAME) coactivator binding. From these inhibitor studies we understand the 
effects of manipulating APC activation and inhibition to achieve therapeutic effects; however, a 
knowledge gap remains regarding the impact of APC-regulatory elements outside of directly 
modulating the CDC20- and CDH1-coactivator binding. There is a broad array of regulatory 
mechanisms influencing APC function based upon regulating complex stability (Tran et al., 2010), 
and post-transcriptional modifications (Zhang et al., 2016) that affect APC E3 ligase activity. The 
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impacts on cellular behaviour through modulating APC behaviour by these mechanisms has not 
been thoroughly investigated, and potentially differ from alterations to CDH1 or CDC20 binding. 
This aspect will be investigated in Chapter 4, where novel peptides which have demonstrated a 
capability for binding and augmenting APC activity will be endogenously expressed in an innately 
MDR breast cancer to examine the effects of altered APC activity on MDR behaviour. 
 There is also the question of the phenotypic alterations imparted upon cancer cells by 
impaired APC activity, and how augmenting APC activity may affect these phenotypes. There are 
multiple cellular pathways that are expected to be altered by augmented APC activity that warrant 
investigation. The relationship between stress responses and APC activity have been explored in 
eukaryotic model systems. Of particular note are the observed interactions between the APC and 
Fkh proteins in yeast to promote stress responses (Malo et al., 2016; Postnikoff et al., 2012,). This 
specific pathway has not yet been examined in mammalian system. In mammalian systems, FOXO 
activity is regulated through AKT signaling, therefore the AKT/FOXO network will be examined 
for alterations upon enhanced APC activity. This pathway is also particularly important as elevated 
AKT activity is a known promoter of MDR behaviour (Goler-Baron et al., 2012; Miller et al., 
2011; Zhou et al., 2013). We will also investigate the implications of augmented APC activity 
with regards to mitotic regulation. Given the essential aspect of APC activity in mitotic 
progression, altering APC activity is likely to affect mitotic regulation in cancer cells, in a manner 
that may support or impair cancer growth and progression. Both of these aspects of cellular 






















Chapter 2. Hypothesis and Objectives 
 
Primary Hypothesis: 
 Decreased APC activity is associated with more aggressive cancer behaviour and correlates 
with the presence of a MDR response to chemotherapy. Therefore, we hypothesize that restoration 
of APC activity will subsequently restore chemosensitivity. 
 
Secondary Hypothesis: 
 We hypothesize that through known APC interactions with stress response pathway 
proteins and influence on mitotic regulation, the targeted enhancement of APC activity will correct 
these defects that promote MDR behaviour, and thereby allow for reversal of chemoresistance.   
 
Objective 1: Generating an in vitro model of APC activity in MDR cancer 
 Currently no established methods exist of directly acting on the APC to enhance its activity. 
Recently a yeast 2-hybrid library was generated which identified novel peptides capable of binding 
discrete APC subunits. Several of these peptides have subsequently demonstrated an ability in S. 
cerevisiae models of APC defects to reverse incurred phenotypes, indicating peptide expression 
enhances APC activity. Due to evolutionary conservation of the APC, these peptides may act in a 
similar manner on the human APC to enhance its activity. To utilize these peptides in human 
models, they will be subcloned into mammalian constitutive expression vectors. Once cloned these 
peptide expressing vectors will be stably transfected into an innately MDR breast cancer cell line 
to endogenously express the peptides. This will permit us to study the phenotypes that arise in 
MDR cancer when APC activity is enhanced. 
 
Objective 2: Establish a relationship between APC activity and MDR behaviour 
 APC E3 ubiquitin ligase activity will be indirectly measured through examining the relative 
abundances of select substrates to identify the peptides most effective at enhancing APC activity. 
A decrease in the accumulation, as identified by Western blotting of APC substrates, will indicate 
an enhancement of the APC E3 ligase activity. The peptides identified as being the most effective 
at enhancing APC activity, as indicated by the greatest reduction substrate levels across multiple 
targets, will be selected for chemosensitivity assays. These assays will consist of treatment with 
the cytotoxic agent doxorubicin (DOX) followed by a reporter assay to quantitate the viability of 
the cell population following treatment. This will be the most direct test of our hypothesis.  
 
Objective 3: Investigate the mechanisms relating APC activity to MDR behaviour 
  Multiple potential mechanisms exist that link enhanced APC activity with MDR 
behaviour. Two mechanisms which are likely relevant to the APC reversing MDR behaviour are 
the induction of stress response pathways and the promotion of a regulated mitosis; two processes 
which are often disrupted in MDR cancers. The specific stress pathway that will be examined is 
the AKT-FOXO3A pathway, which when manipulated to inhibit AKT promotes FOXO3A activity 
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and initiates a stress response and apoptosis. The second mechanism being investigated is the role 
of the APC in promoting a regulated mitotic cycle. Enhanced activity of the APC may act to correct 
the dysregulated mitosis normally occurring in MDR cells. To measure this, fluorescent 
microscopy utilizing a DNA stain will permit visualization of mitotic events. Quantification of 
improper mitotic events (referred to as mitotic catastrophes) will be the measure of how mitotic 
regulation is after peptide expression. One consequence of a dysregulated cell cycle is the 
accumulation of DNA damage, which will also be analyzed through γH2A.X abundance, which is 


































Chapter 3. Methods and Materials 
 
3.1 Yeast Peptide Cloning into a Human Expression Vector 
 
 Polymerase chain reaction (PCR) amplification was performed on each peptide using the 
original yeast plasmids as a template. The orientation of the peptides from the N-terminus: SV40 
nuclear localization signal (NLS, sequence PKKKRKV), B42 transcriptional activating domain, 
Haemagglutinin (HA, sequence YPYDVPDYA) tag, thioredoxin (TrxA), peptide, TrxA. All PCR 
reactions utilized the same 3’ primer, binding after the C-terminus of the second TrxA sequence. 
Two 5’ primers were utilized in separate reactions to produce two distinct insert sequences from 
the same original sequence. One 5’ primer bound 3’ of the B42 sequence (producing a DNA 
fragment without the NLS, or B42 sequences) and one primer bound 5’ of the NLS (producing a 
DNA fragment with the NLS and B42 sequences). All amplified sequences contain HA-TrxA-
peptide-TrxA. PCR sequences were then incubated with 0.5 units/μL Taq polymerase (New 
England Biolabs, Whitby, ON, Canada) at 70°C for 30 min in 1x Taq buffer (supplemented with 
0.2 mM dNTP and 2.5 mM MgCl2) to produce thymidine overhangs. PCR products were then 
purified with Zymo DNA purification and concentration columns following manufacturers 
protocol (Burlington, ON, Canada). After purification, insert sequences were ligated into pGEM-
T Easy vector (Promega, Madison WI, USA) via TA ligation following the manufacturer’s 
instructions and transformed into the Escherichia coli (E. coli) strain DH5α (Thermo Fisher 
Canada, Mississauga, ON, Canada). Transformed E. coli were then incubated on Luria Broth (LB)-
Agar plates (0.5% w/v yeast extract, 1% w/v tryptone, 171 mM NaCl, 0.2% agar) supplemented 
with the antibiotic ampicillin (0.1 mg/mL) and blue/white screening (20 mg/mL X-gal [5-bromo-
4-chloro-3-indolyl-β-D-galactopyranoside] and 100 mM IPTG [Isopropyl β- d-1-
thiogalactopyranoside]). White bacterial colonies were then cultured in LB (with 0.1 mg/mL 
ampicillin, LBA) for plasmid amplification at 37°C for 16 hrs with agitation. The plasmids were 
then purified using phenol-chloroform purification (Appendix A.4). Insert sequences were then 
verified by restriction digests using BamHI (Thermo Fisher) and XhoI (Thermo Fisher) following 
the manufacturer’s protocol. Insert fragments were then purified via gel extraction (Appendix A.5) 
and ligated into pcDNA 3.1 (Thermo Fisher) previously restricted with BamHI and XhoI using T4 
ligase following manufactures protocol. Plasmids were then transformed into DH5α and plasmid 
DNA purified using the phenol-chloroform extraction method. Sanger sequencing performed by 
the National Research Council (Saskatoon, SK, Canada) confirmed proper insertion of the peptides 
into pcDNA3.1 and confirmed the correct reading frames between epitope tags and proteins. 
 
3.2 Cell Culture and Plasmid Transfection 
 
 The TNBC cell line MDA-MB-231 (231) was commercially obtained from the American 
Type Culture Collection (ATCC; Manassas, VA, USA). Cells were grown in Dulbecco’s Modified 
Eagle’s Media (DMEM, Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine 
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serum (FBS, Invitrogen), 1X Ab/Am (100U/mL penicillin, 100 mg/mL streptomycin, 0.25 µg/mL 
of Amphotericin B [Invitrogen]) unless otherwise stated. Incubators were maintained at 37°C and 
5% CO2. Cells were transfected using Lipofectamine 3000 (Thermo Fisher), following the 
manufacturer’s protocol. Stable integration of the plasmids was performed by persistent exposure 
to the neomycin analogue geneticin (Invitrogen) in 2%, 3%, and 4% increments for 48 hr each.  
 
3.3 Western Blotting 
 
 Western blotting was performed as previously described (Davies et al., 2009). Cells were 
harvested from the cell culture dishes in 1 mL 1x phosphate buffered saline (PBS; 0.067M PO4) 
with a rubber policeman. Cells were then pelleted at 10,000 rpm for 2 minutes and the PBS 
decanted. The pellet was then resuspended in 100 μL 1X radioimmunoprecipitation (RIPA) buffer 
(20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 10% glycerol, 0.5 mM Ethylenediaminetetraacetic 
Acid [EDTA], 0.1 mM Egtazic acid [EGTA], 0.1% sodium dodecyl sulfate [SDS] plus 1X 
mammalian cell anti-protease cocktail [MilliporeSigma Canada, Oakville, ON, Canada]). Cells 
were then lysed via pulse sonication and centrifuged at 18,000 rpm and 4°C for 5 minutes. The 
supernatant was decanted, and the pellet discarded. The commercial Bradford assay (BioRad 
Protein Reagent; BioRad Laboratories, Hercules, CA, USA) quantified protein content in the lysate 
based on a standard curve in a SmartSpec 3000 (BioRad). A lysate aliquot was then diluted into 
100μL of RIPA (to reach desired concentration) then protein sample of protein was denatured with 
a 5x sample buffer (5x loading buffer [250 mM Tris HCl pH 6.8, 10% w/v SDS], 15% v/v 2- 
mercaptoethanol, 30% v/v glycerol, and trace bromophenol blue) and boiled for 2 min. Lysates 
were then run an acrylamide gel between 7.5% and 15% at 150V. The gel was then transferred 
onto a nitrocellulose membrane (BioRad) in 1X transfer buffer (0.19 M glycine, 25 mM tris base, 
10% v/v methanol) at 90V for 1.5 hrs. After transfer, membranes were stained with Ponceau S 
(0.1% (w/v) Ponceau S [Thermo Fisher] in 1% v/v acetic acid) as a non-specific protein stain and 
imaged with a photocopier to document the relative loads. Ponceau S was then washed from the 
membrane with two washes in 1x PBS with 1% Tween 20 (PBST) for 5 min each, with agitation. 
The membrane was then blocked with a 5% w/v skim milk 1X PBST solution at room temp (RT) 
for one hr. Primary antibody incubation occurred with either 1:1000 (total protein) or 1:500 
(phosphor-protein) dilutions in 5% skim milk PBST overnight at 4°C. Membranes were then 
washed 3 times for 10 min in 5% skim milk PBST at RT. The membrane was then incubated in a 
1:10,000 secondary antibody-horseradish peroxidase conjugates (HRP) dilution in 5% skim milk 
PBST solution for 1 hr at RT. Three 10 min washes were then performed with 1X PBST. This was 
followed by a 5 min incubation with enhanced chemiluminescent reagent (ECL, BioRad) permitted 
imaging with a VersaDoc and analysis with the QuantitiyOne software (BioRad; version 4.6.9).   
 
3.4 Cellular Viability Assays 
 
 Viability assays were performed as previously described (Davies et al., 2009). Cells were 
grown to 50% confluence and subject to doxorubicin hydrochloride (DOX; Pfizer, Brandon, 
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Manitoba, Canada) treatment for 48 hours in DMEM. The cells were then incubated for 2 hours 
with phenol red free DMEM media supplemented with 10% FBS, and 2% 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT; MilliporeSigma) solution. Cells were then 
solubilized with 99.5% dimethyl sulfoxide (DMSO) for absorbance spectrophotometry at λ570 nm 
with a SmartSpec 3000 (BioRad).   
 
3.5 Immunofluorescence  
 
 Cells were grown on coverslips to 60% confluence. They were fixed by incubation in 4% 
paraformaldehyde for 10 min at RT then washed twice with 1X PBS and stored at 4oC. Cells were 
permeabilized by incubation in 0.5% Triton X-100 for 10 min followed by 0.05% Triton X-100 
for 5 min. Cells were incubated with a 1:200 primary antibody dilution in 1% bovine serum 
albumin (BSA) for 1 hour in a humidity chamber at RT. Cells were washed with 0.05% Triton X-
100 then incubated with a 1:200 secondary fluorescent antibody dilution in 1% BSA for 1 hour in 
a humidity chamber at RT. Cells were then washed with 0.05% Triton X-100 for 5 min at RT. 
Cells were then placed on cover slips onto 4′,6-diamidino-2-phenylindole (DAPI) droplets and the 
edges sealed with nail polish and stored at 4°C. 
 
3.6 Kinome Array 
 
 The array was performed by collaborators in Dr. Nappers’ lab (University of 
Saskatchewan), whereas the data analysis and pathway construction was done by us. The array 
was performed as described previously (Määttanen et al., 2013). Briefly, cells from our strains of 
interest were harvested from cell culture dishes into 1x PBS with a rubber policeman and pelleted 
at 10,000 rpm for 2 minutes, and decanted. The pellet was then resuspended in lysis buffer (20 
mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium 
pyrophosphate, 1 mM Na3VO4, 1 mM NaF, 1 μg/ml leupeptin, 1 μg/ml aprotinin, 1 mM PMSF, 1 
μg/ml pepstatin A, and 2 mM dithiothreitol [DTT] [all products from Sigma-Aldrich unless 
otherwise indicated]) and vortexed. The homogenate was diluted 8-fold in ice cold lysis buffer, 
vortexed, and incubated for 20 min on ice to permit lysis. The lysates were then further diluted to 
achieve a protein concentration between 1.0-1.5 mg/mL as according to the Bio-Rad Bradford 
method. A 70 μl aliquot of supernatant was mixed with 10 μL of activation mix ((50% glycerol, 
500 μM ATP [New England BioLabs], 60 mM MgCl2, 0.05% vol/vol Brij 35, 0.25 mg/ml BSA) 
and incubated on the array for 2 h at 37°C. Arrays were then washed with 1% Triton X-100.  
 Slides were then submerged in a phosphor-specific fluorescent ProQ Diamond 
phosphoprotein stain (Invitrogen) while being agitated for 1 hour followed by to 3 washes in a 
20% acetonitrile (EMD Biosciences [VWR distributor], Mississauga, Ontario, Canada), 50 mM 
sodium acetate (MilliporeSigma) pH 4.0 destain solution for 10 min. A final wash with ddH2O 
was performed prior to 20 min air drying. Slides were then centrifuged at 300 x g for 2 min to 
remove residual moisture. Arrays were analyzed with a GenePiX Professional 4200A microarray 
scanner (MDS Analytical Technologies, Toronto, Ontario, Canada) at 530 to 560 nm with a 580-
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nm filter. Images were collected using the GENEPix 6.0 software (MDS). Spot intensity signals 
were collected as the mean of pixel intensity using the local feature background intensity 
calculation with the default scanner saturation level. The local background intensities were 
subtracted from foreground intensities, and the resulting value transformed with variance-
stabilizing normalization to eliminate variance-versus-mean dependence and normalize the data 
for easier analysis. The resulting data set contained signal intensities from 3 technical repeats (per 





 pan-AKT ab8805 (Abcam; Cambridge, MA, USA) 
 p-AKT S473 ab81283 (Abcam) 
 BCRP sc-377176 (Santa-Cruz Biotechnology; Dallas, TX, USA) 
 Cyclin A2 ab38 (Abcam) 
 Cyclin B1 C8831 (SigmaMilliPore) 
 CDC20 PA5-34775 (Thermo) 
 FOXO3A ab70315 (Abcam) 
 p-FOXO3A ab47285 (Abcam) 
 γ-H2A.X H5912 (SigmaMillipore) 
 HURP ab80684 (Abcam)  
 MDR1 sc55510 (Santa-Cruz) 
 NEK2A ab115731 (Abcam) 
 PPP1CA ab137512 (Abcam) 
 p-PPP1CA T320 ab62334 (Abcam)  
 Rabbit HRP 170-6515 (BioRad) 
 Mouse HRP 170-6516 (BioRad) 
 
 Enzymes: 
 Taq Polymerase M0267S (New England Biolabs) 
 Phusion HS II F549S (Thermo) 
 BamHI FD0054 (Thermo Fisher) 
 XhoI FD0694 (Thermo Fisher) 
 T4 Ligase M0202S (New England Biolabs) 
 
 Kits: 
 Caspase Kit ab219915 (Abcam) 
 PGEM-T Easy A1360 (Promega) 
 Lipofectamine 3000 L3000008 (Thermo Fisher) 
 E. coli (DH5α) 18265017 (Thermo Fisher) 
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Chapter 4. Modulating Cancer Behavior by Enhancing APC Activity in 




4.1.1 Overview of the Anaphase Promoting Complex 
 The Anaphase Promoting Complex (APC) is an E3 ubiquitin (Ub) ligase and performs a 
myriad of functions necessary for the proper functioning and health of the cell. As a fundamental 
function, E3 ubiquitin ligases select and target specific proteins for regulated degradation by the 
proteasome. For the APC, this target selection occurs in coordination with the cell cycle 
(Sivakumar et al., 2015). There are multiple critical consequences of normal APC action including 
promoting a regulated mitotic progression, inducing stress response pathways and therefore the 
balance between apoptosis and cellular progression, as well as ensuring genomic stability through 
regulating mitosis, DNA replication and DNA repair mechanisms. Therefore, disruption of APC 
activity results in loss of cell cycle regulation, genomic instability, and impaired stress responses 
(Basserman et al., 2008; Greil et al., 2016; Harkness, 2018; Simpson-Lavy et al., 2009; Sodu et 
al., 2001). These phenotypes are common characteristics of cancer development and progression 
into more aggressive behaviours, and therefore loss of APC activity may promote malignant 
behaviors (Hanahan and Weinberg, 2011). 
 The APC is highly controlled both through regulated suppression and activation 
mechanisms, including common themes of post translational modifications in concert with the 
position of the cell cycle, as well as the subunit composition of the APC complex itself. The APC 
is activated by the mutually exclusive physical association of two coactivators, CDC20 and CDH1, 
each with unique roles in APC activity and at distinct positions within the cell cycle (Kramer et 
al., 2000; Visitin et al., 1997). In addition, the protein(s) selected for Ub-mediated degradation can 
depend on which of the two coactivators is bound (Pfelger et al., 2000). An example of regulated 
APC suppression is elegantly presented by considering the sequestration of CDC20 by the SAC 
prior to metaphase (Pan and Chen, 2004). During metaphase (prior to chromosomal alignment) 
the APC remains inactive as the SAC sequesters CDC20 and CDH1 is at low levels and unable to 
bind and activate the E3. Upon proper alignment of the chromosomes, the SAC becomes 
inactivated and releases CDC20, which then binds to the APC to form APCCDC20. The now active 
APCCDC20 is then free to perform polyubiquitination, to promote chromosomal segregation, and 
progression through anaphase, and telophase by targeting proteins for degradation that normally 
prevent progression (Luo and Tong, 2017; Sivakumar et al., 2015). During mitotic exit CDC20 
will dissociate from the APC, being replaced by CDH1 forming APCCDH1 (Kramer et al., 2000; 
Visintin et al., 1997). This complex will persist until S phase as CDH1 is slowly degraded by 




4.1.2 APC dysfunction and cancer: 
 A controversy currently exists as to whether the APC should be targeted for inhibition or 
activation as a therapeutic approach to treating cancer. This is due to the contradictory roles of the 
APC coactivators CDC20 and CDH1 in cancer development and progression. Overexpression of 
CDC20 has been identified as a prognostic marker for poor clinical outcomes for multiple 
unrelated cancer types including gastric (Ding et al., 2014), breast (Karra et al., 2014), colorectal 
(Wu et al., 2013), prostate (Mao et al., 2016), brain astrocytoma (Ding et al., 2017) and pancreatic 
cancer (Chang et al., 2012). Briefly, CDC20 overexpression promotes malignant behaviour 
through overriding mitotic arrest induced by the SAC through excessive CDC20 accumulation in 
the cell, and promoting a dysregulated mitotic progression despite normal SAC activity (Bonauiti 
et al., 2014; Pan et al., 2004).  
 Conversely, impaired CDH1 activity promotes cancer progression, as it normally functions 
as a tumor suppressor. CDH1 haploinsufficient mice (CDH1 +/-) experience elevated instances of 
cancer development (Garcí-Higuera et al., 2008). Furthermore, prolonged suppression of CDH1 
results in acquired resistance to radiation therapy in mouse models of B cell lymphoma (Ishizawa 
et al., 2017). CDH1 promotes multiple functions of the APC to act in a tumor suppressive manner 
(Wäsch et al., 2010). Examples include the necessary role of CDH1 activity in the induction of 
stress responses (Simpson-Lavy et al., 2008; Sudo et al., 2001), checkpoint activation (Basserman 
et al., 2008; Cappell et al., 2016) and cell cycle regulation (Choudhurry et al., 2016; Park et al., 
2008; Sigi et al., 2009), mechanisms commonly disrupted in cancer. However, CDH1 also has 
oncogenic potential as it is capable of overriding SAC inhibition and inducing mitotic slippage 
(Nagai et al., 2014; Park et al., 2018; Toda et al., 2012). Mitotic slippage refers to the process 
whereby, despite the activation of the SAC inducing mitotic arrest due to detection of DNA 
damage, the cell progresses into anaphase. Consequences of mitotic slippage include dysregulated 
proliferation, aneuploidy, and accrual of DNA damage (Crasta et al., 2012; Ohashi et al., 2015; 
Zhu et al., 2014). The frequent correlation between accumulated APC substrates and more 
aggressive malignant tumor behaviors indicates that a generalized disruption of APC activity may 
occur during cancer progression (Lehman et al., 2007; Zhang et al., 2019). Impairment of APC 
activity may also arise through defects in the complex itself. Mutation or decreased expression of 
APC subunits APC6, APC8, APC7, and APC16, permits the unregulated proliferation of cells and 
promotes cancer development and progression (Wild al., 2018; Wang et al., 2003), whereas 
deletion of other subunits causing severe loss of APC activity is lethal to even normal cells given 
its essential function. The disruption of APC activity has also been observed during the progression 
of canine lymphoma into an MDR state, where elevated APC activity corresponded with remission 
/chemosensitivity, whereas relapse correlated with APC dysfunction (Arnason unpublished).  
  
4.1.3 Targeting APC as a therapeutic route to improving cancer responsiveness   
 Enhancing APC activity has generated great interest as a therapeutic possibility in the 
treatment of cancer. Currently, in vitro activation of the APC has been achieved through 
pharmacological inhibition of two SAC components, MAD2 and the TTK protein kinase. These 
agents have been designated MAD2 inhibitor 1 (M2I-1) and TTK protein kinase inhibitors (TTKi) 
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respectively. By targeting either subunit of the SAC, these agents induce their therapeutic effect 
through SAC impairment to elevate CDC20 availability, permitting its association with and 
activation of the APC (Kastl et al., 2015; Wang et al., 2019). In vitro, either agent alone or in 
combination with additional chemotherapies induced cell death and demonstrated potent anti-
tumorigenic activity, with several TTKi treatments currently undergoing clinical trials (Maia et 
al., 2018; Thu et al., 2018; Wenger et al., 2016). While much remains to be determined, it is 
thought that the therapeutically activated APC forces cancerous cells to undergo mitotic slippage, 
and incur the aforementioned consequences (Kastl et al., 2015; Li et al., 2019; Maia et al., 2018; 
Thu et al., 2018; Wengner et al., 2016). Due to the role of TTK in regulating proper chromosomal 
segregation, there remains concerns about potential TTK inhibitor toxicity in proliferative non-
cancerous cells (Martinez et al., 2015). As of yet, there have been no agents capable of enhancing 
APC activity through directly binding the APC complex. 
 
4.1.4 Direct activation of the APC through novel peptides  
 A series of novel peptides have been identified using a yeast 2-hybrid library as being 
capable of physically binding the APC, through either of the APC subunits APC5 or APC10. To 
investigate the interactions between these peptides and the APC, yeast strains harboring mutations 
in APC activity were utilized to examine the impact of peptide expression on APC phenotypes. 
Mutated APC in yeast can give rise to temperature sensitive growth, and marked decreases in yeast 
lifespan. Significantly, multiple peptides found to directly bind the APC were also capable of 
restoring the temperature sensitivity defect and of enhancing the replicative lifespans back to that 
of wild-type unmutated yeast strains. Due to the evolutionary conservation of the APC, including 
the APC5 and APC10 subunits, it is hypothesized these peptides will have a similar activating 
effect in mammalian cells (data unpublished). 
 Mammalian cells are not readily testable for lifespan or temperature sensitivity, such as is 
used to assess yeast APC mutants. Rather, direct and indirect measures of APC activity can be 
made in mammalian cells. The E3 ligase function of the APC can be semi-quantitatively measured 
through in vitro ubiquitination assays. Comparison of polyUb chain formation and chain 
abundance on known APC substrate proteins can identify the relative changes in APC E3 activity 
(Kraft et al.,2006). The impact of the novel peptides on APC activity can also be indirectly 
measured through the accumulation of APC substrates, and dysfunctional APC would accumulate 
normally degraded protein substrates, whereas activation of the APC would decrease protein 
abundance. 
 
4.2 Materials and Methods 
 
4.2.1 Creation of human peptide expression plasmids: Peptide Cloning 
 Random peptides were generated and then analyzed in a yeast 2-hybrid library to identify 
peptides capable of binding select subunits of the APC. Several peptides later demonstrated an 
ability to promote APC activity in yeast (data not shown), and were therefore cloned into 
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mammalian expression vectors was previously described in section 3.1. In order to promote small 
peptide stability, peptide-protein hybrids were constructed whereby the larger TrxA backbone 
provides stability to the smaller peptides of interest, and are unchanged from the protein expressed 
in yeast (only the promoter and selectable marker differ). From the proteins’ N-terminus, a 
Haemagglutinin epitope tag (HA, sequence YPYDVPDYA) is fused in frame to the first 
thioredoxin subunit (TrxA, Escherichia coli) and separated from the second TrxA subunit by an 
in-frame peptide fusion (Figure 4.1 A). A second version of each peptide was created to include 
an SV40 nuclear localization sequence (NLS, sequence PKKKRKV) and a B42 transcriptional 
activating domain (enhances sensitivity in the yeast 2-hybrid library) to the peptide/protein hybrid; 
the remainder of the expressed peptide-protein hybrid was not altered otherwise (Figure 4.1 B).  
 Sanger sequencing was performed by The National Research Council (Saskatoon, SK) to 
confirm the proper in-frame insertion of the peptides into the backbone. It was noted that several 
peptides, in both the yeast and human peptide constructs, had a premature stop codon in the TrxA-
peptide-TrxA DNA sequence through either a frame shift in the second TrxA subunit or via a stop 
codon within the peptide sequence itself (Table 4.1). The vector backbone used for human peptide 
expression is pcDNA3.1 (pcDNA), and contains CMV and T7 constitutive promoters. The pcDNA 
backbone was selected because of its constitutive expression permitted the observation of long-
term affects of peptide expression on APC activity.  
    
Figure 4.1. Insert constructs inserted into the pcDNA backbone. Sequences of the 
protein constructs inserted into pcDNA backbone. A) The insert without an NLS 
present. B) The peptide inserts with a SV40 NLS, and a B42 subunit to the backbone. 
C) Ribbon diagram represents the 2 domains of the E. coli thioredoxin protein, 
highlighting the position of the peptide insertions with a dotted red circle between the 





Predicted amino acid sequences of the peptides Premature 
Stop 
Bound APC Subunit 





C1.8 FCL* *GLSLLHLTFVPFGQL 
 
 
Yes APC5 6.0 
C2.4B RMPQWWQWM Yes APC5 & APC10 7.6 
C3.1 GRMLMTYLWYFMVLWVPRPWGPPLGLRGMWN*RFMNCP
LVFLGPLSSGGEGFLYPWRL*LGESD 
Yes APC5 9.4 
C3.1B VNGERWAP*SPNPRALCVL*GPLQSVGLFQHGNQGERWER
LL 
Yes APC10 6.55 
C9.5 CECLETETFHPITRHLIVPV No APC5 9.9 
C13.3 GALKEVCICIVESVGGEVFS No APC5 10.9 
C43.4 NGSSHNDLRVRRLTLISRLC No APC10 9.9 
 
Table 4.1. Characteristics of the peptides. The amino acid sequences of the peptides, whether they induce a 
premature stop codon in the protein backbone, and the APC subunit bound. Premature stop codons in the DNA 




Name Gene ID Start Alignment with peptide End % Identity % Positives 
Peptide C13.3 
 
1 GALKEVCICIVESVGGEVFS 20   
Cytokine SCM-1 beta precursor NP002986.1 11     GALKEVCICIVEGVGSEVFS 26 56 56 
Tetratricopeptide Repeat Protein XP016860458.1 740     GALKEVCICIVETVGGEVFS 747 88 87 
VitK Epoxide reductase complex XP011514133.1 106     GALKEFCICIVESVGGEVFS 115 80 80 
Sodium/Hydrogen exchanger 9B2 
Isoform 
NP001287685.1 
143     GALKGVCXXCIVEVGGEVFS 158 50 56 
5-Oxoprolinase NP060040.1 717     GALKEVCICI--SVAGEVFS 725 73 72 
Phosphatidylinosital 3,4,5-
triphosphate/Rac exchanger 2 
XP011515914.1 
1036     GALKEVCVCIVESVGGEVFS 1045 70 80 
AMPK  1 subunit NP001341964.1 329     GALREVCFCVVESVGGEVFS 339 64 72 
APC1 subunit NP073153.1 146     GALKEVCICILESVGGEVFS 156 64 72 
Rab-21 Ras-related protein NP055814.1 124     GALKEICLCIVESVGGEVFS 130 71 85 
B) 
Name Gene ID Start Alignment with peptide End % Identity % Positives 
Peptide 43.4 
 
1 NGSSHNDLRVRRLTLISRLC 20   
CD14 Monocyte Differentiation antigen NP000582.1 
89 NGSSHNDLRVRRLTLISRLC 95 
100 100 
257 NGSSHNSLRVRRLTLISRLC 262 
Solute carrier family 6 member 2 X3 XP016881489.1 167 NGSSHNDLRVRRLTLISRLC 182 63 62 
N- acetyltransferase 25 XP016875466.1 
336 NGSSHNDLRIRSLTL--RLC 345 67 75 
548 NGSSHNDLRVRRLTLISRLC 551 100 100 
CDK12 isoform14 XP005257515.1 945 NGSSHNDLRVRRLELISRLC 952 88 87 
Eukaryotic initiation factor 3 XP016879110.1 116 NGSSHNDLRVRILTLVERMC 135 55 65 
HERC 6 probably E3 Ub-ligase XP06863822.1 266 NGSSHNDLRVRR----SRLC 273 67 66 
SUN-domain containing protein 2 XP016884237.1 
98 NGSSHNDLRVRRLTLISRLC 103 100 100 
406 NGSSVKEL--RRLTLISRLC 414 55 63 
335 NGSSHNDLRVRRLTLVSRLC 338 54 69 
Neuron navigator 2 isoform 
XP011518756.1 690 NGTAQSDLRIRRLTLISRLC 702 54 69 
964 NGSSHNDLRVRRLTLISRLC 967 100 100 
Serine-rich coiled-coildomain protein XP016863690.1 7 NGSSHNDLRVRRSTLVSRLC 15 78 88 
Table 4.2. Sequence homologies of peptides to human proteins. Sequence alignment of A) C13.3 and B) C43.4. Black indicates 




4.2.2 Cell Culture 
 The protocol was previously described in section 3.2 
 
4.2.3 Western Blotting 
 The protocol was previously described in section 3.3. Imaging was performed with a 
VersaDoc (Bio Rad), and analyzed using VersaDoc software Quantity One (version 4.6.9).  
 
4.2.4 Chemosensitivity Assays 
 The protocol to measure cell survival after exposure to cytotoxic chemotherapy was 
previously described in section 3.4. Two formats were used, a 6-well format and a 96-well format. 
The 6-well format exclusively utilized a 1 μM dose of doxorubicin (DOX) for 48 hours. Here, each 
trial consisted of 3 control wells and 3 treated wells, repeated 3 times. The 96-well format utilized 
a range of DOX doses from 0 to 1 μM, with 0.1 μM increments of DOX, for 48 hours. Each trial 
consisted of 4 control wells and 4 treated wells at each concentration, repeated 3 times. 
 
4.2.5 Statistical Analysis 
 Unpaired t-tests were performed between the control cell line and individual peptide 
expressing cell lines to determine statistical significance. Statistical analysis was performed within 
the software of GraphPad Prism version 8.4.1. Confidence intervals were established by our 
collaborator Dr. Rana (University of Saskatchewan) utilizing a non-linear regression model with 
classical models of inference, a confidence interval was established to determine statistical 
significance in the dose-response curve, with an alpha level of 0.05 for hypothesis testing. 
Confidence intervals were generated in a R statistical environment (R Core Team, 2017) using the 




4.3.1 Determining the necessity for a Nuclear Localization Signal (NLS) sequence for 
peptide biological efficiency in human cells. 
 Because the APC complex and its E3 activity is reported to be exclusively localized to the 
nucleus (Sivakumar et al., 2015), we queried if an NLS was required in our mammalian peptide 
expression constructs to enable a biological effect on APC activity. Therefore, two variants of each 
APC-activating peptide were produced for human cell expression. One version contained an in-
frame NLS and one was expressed without, with no differences otherwise. Our preliminary screen 
to indirectly detect changes APC activity was performed utilizing western blotting of the APC 
substrates CDC20 and Cyclin B1 to determine if an NLS was essential to peptide function. 
Enhanced activity would result in increased degradation of the APC substrates via its E3 Ub-ligase 
activity. The results with peptides C1.8, C2.4B, C13.3 and C43.4 reveal that peptides without an 
NLS were more effective at reducing the accumulation of APC substrates (Figure 4.2). Additional 
peptides C3.1, C3.1B, and C9.5 were also examined and produced similar results (data not shown). 
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Therefore, experimentation with the NLS peptide variants was discontinued, and all following 




Figure 4.2. Determining the necessity of an in-frame peptide nuclear localization 
signal on indirect APC activity. Representative western blots of whole cell lysates 
prepared from 231-cells stably transfected with four different constitutively expressed 
peptides comparing the ability of peptides to induce APC activity with (+) and without 
(-) an N-terminal NLS. CDC20 and Cyclin B1 are known APC degradation targets. 
The load control is Tubulin. The control is a 231-cell line stably transfected with an 
empty pcDNA vector.  
 
4.3.2 Cloning and detection of peptide expression constructs in an MDR human cell line 
 The peptide amino acids are embedded within the two lobes of the stable thioredoxin 
protein, which itself is 6.55 kDa in size (Figure 4.1C). Due to the existence of a premature stop 
codons in many peptide sequences (Table 4.1), the second globular TrxA- domain is missing from 
several peptides. Therefore, their molecular weights as predicted from sequencing range from 5.87 
kDa to 10.88 kDa. Sequencing confirmed the in-frame cloning of the HA-TrxA-peptide sequences 
within the pcDNA vector, and revealed the expected molecular weight of each construct (Table 
4.1).   
 The N-terminal HA epitope is expected to be detectable by anti-HA western blotting, to 
confirm expression after stable transfection. Initially, expression of C13.3 and C43.4 could be 
verified after stable transfection into 231 cells through HA blotting (Figure 4.3). However, these 
blots were later revealed to be non-specific background signaling. This was a result of an incorrect 
calculation of the full weight of the peptides, and the assumption that we were working with the 
full length bacterial thioredoxin (weight of 24 kDa), which when combined with most peptides 
would weigh around 30 kDa. This error was discovered from calculating the exact molecular 
weights acquired from the sequencing results and unfortunately, we have not been able to correctly 






Figure 4.3. Detection of peptide expression. Whole cell lysates were prepared from 
eight 231 cell populations individually (stably) transfected with empty pcDNA vector 
(control) or one of seven constitutively expressed peptides, as indicated. A Western 
blot was performed from these cell lysates against the HA tag present at the N-terminus 
of each thioredoxin-peptide conjugate, with predicted weights between 6.0 and 10.9 
kDa (Table 4.1). The 15 kDa marker represents the bottom/front of the acrylamide gel 
and is not resolved. The control is an empty pcDNA vector and does not have the HA 
epitope.  
 
4.3.3 Indirect assessment of changes in APC activity upon constitutive peptide expression. 
 APC activity can be determined indirectly by qualitatively and quantitatively measuring 
the protein abundance of several known APC protein degradation targets, with the expectation that 
enhanced APC activity would be detectable as a decrease in target signal as compared to control. 
The degradation of substrates that simultaneously regulate APC activity may also yield insights 
into APC regulation. The degradation of Cyclin B1 by APCCDC20 is necessary for the transition of 
the APC to CDH1 driven activity, as Cyclin B1-promoted phosphorylation inhibits APCCDH1 
binding (Sivakumar 2015). Remaining Cyclin B1 is then degraded by APCCDH1 during mitotic exit 
simultaneously with CDC20. It is important to examine APC activity outside of the context of 
APC regulation, so we determined the relative abundance of three independent APC targets, Cyclin 
B1, HURP and CDC20 (Figure 4.4). Peptide C43.4 produced the greatest decrease in two of the 
three APC substrates, and therefore presumably reflects a stronger increase in APC activity than 
any of the other peptides. In the presence of C43.4 versus control, a marked reduction in the protein 
abundance of Cyclin B1, HURP, and CDC20 was noted, a statistically significance difference for 
Cyclin B1 and HURP (49.9% [p<0.0001], 30.7% [p=0.0047] and 58.3% [p=0.2372], of the control, 
respectively). C13.3 also demonstrated increased APC activity, given the marked reduction of all 
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three targets as compared to control, reaching significance for Cyclin B1 (73.9% reduction: 
p<0.0001), and HURP (44.4% reduction: [p=0.0316], but not for CDC20 (49.3% reduction: 
[p=0.0702]. Other peptides were also capable of reducing substrate quantities, but in an 
inconsistent manner. C1.8 reduced CDC20 to 61.9% (p=0.0434), and C3.1 reduced HURP to 
57.0% (p=0.0240) of control. Other peptides also approached statistically significant degradation 
of one or multiple substrates. The consistency of substrate degradation induced by C13.3 and 
C43.4 suggested that these two peptides provide enhancement to APC activity, with C43.4 
producing the greater effect. The remaining peptides were excluded from further analysis.   
Figure 4.4. Indirect assessment of APC activity changes with constitutive peptide 
expression. (A) Qualitative representative Western blots of three APC protein 
degradation targets HURP, CDC20 and Cyclin B1 expressed by stable transfection in 
231 cells. Quantitative representation of (B) HURP, (C) CDC20 and (D) Cyclin B1 
protein abundance adjusted for the GAPDH load control, and normalized to the control 
[231 cell line stably transfected with an empty pcDNA vector], set to 1.00. n=3 
biological repeats. Unpaired t-tests between control and individual peptides was 
performed to establish statistical significance; *=p<0.05, **=p<0.01,  ****=p<0.0001. 
Error bars represent standard error of the mean (SEM).  
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4.3.4 Assessment of changes to MDR cell line chemosensitivity upon peptide expression. 
 Our observation that MDR cells lines and tumors had lowered APC activity than matched 
parental cell lines or control tissue had led us to hypothesize that increasing APC activity would 
restore the cellular death in response to chemotherapy (Arnason, unpublished) and restore 
chemosensitivity. The previous experiments (Figure 4.4) had revealed that both the C13.3 and 
C43.4 peptides were significantly able to increase the E3 ligase activity of the APC, at the level of 
target protein degradation. Next, we wanted to determine if the augmented activity of the APC 
induced by these two peptides would enhance the cell death in response to chemotherapy, 
measured as a reduced cell viability compared to the 231 MDR cell line without peptide 
expression. There are multiple ways to assess cell viability, and here we use the MTT assay, a 
colourimetric assay where only living cells can convert the assay reagent to a visible spectrum 
color (λ570) over a linear range. For each cell line/peptide combination, a dose of the 
chemotherapeutic DOX was delivered. After 48 hrs of treatment with DOX, cells are incubated 
with the MTT reagent; surviving cells metabolize the MTT into Formazan (purple) that can be 
quantitated through absorbance spectrophotometry after solubilization of the cells in DMSO.   
 Chemosensitivity assays were first carried out using our standard 6-well growth chamber 
format, allowing for triplicate repeats for each cell line with and without exposure to a near-lethal 
dose of 1.0 μM DOX. The control 231 MDR cell line was compared to 231 cells expressing either 
C13.3 or C43.4 (Figure 4.5 A). This dose caused an 83.5 % mortality rate (16.5% viability) in the 
control line which was minimally increased to 84.5% upon C13.3 expression (15.5% viability) and 
to 89.9% mortality rate upon C43.4 expression (10.1% viability).  
 Although the peptides appear to enhance cell death, the extensive killing of the control 
strain minimized our ability to see strong differences and therefore to make conclusions. 
Considering that the 1.0 μM DOX dosing was too potent to facilitate the detection of 
chemosensitivity differences between the peptides, we developed a DOX-dose-response MTT 
assay using a 96-well format. The DOX concentration increased by 0.1 μM increments from 0.1 
μM to 1.0 μM (Figure 4.5 B) and demonstrated a clear separation between the chemosensitivity 
of 231 cell populations expressing peptide, versus without, and with C43.4 exhibiting a more 
potent cell killing than C13.3 at any given dose. The separation of differential chemosensitivities 
occurs at DOX concentrations of >0.5 μM. Beginning at the 0.5 μM dose, both peptides begin to 
diverge from the trend established by the control, and continue to enhance cellular death with the 
incremental dosage increases. C43.4 produces the strongest effect in elevating chemosensitivity, 
with an almost universally strong response to treatment at each dose level when compared to the 
control. A clear separation between 95% confidence intervals at DOX doses > 0.5 μM between 
peptide expressing 231 cells and the control serves as a visual confirmation that the observed 
elevated response is statistically significant. (Figure 4.4 C).  
 The 1.0 μM dose, as performed in the 6-well format demonstrated itself an inappropriate 
measurement for cellular viability as the severe drop in viability between the 0.9 μM and 1.0 μM 
dose converged the divergent trends in chemosensitivity (Figure 4.5 B) between the peptide 
expressing cell lines and the control. The 1.0 μM dose demonstrated excessive potency, and 
overrode the impact of enhanced APC activity on chemosensitivity. By examining the lower doses 
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(0.5 μM-0.9 μM) presented in the 96-well format, a clear trend is present, that elevated APC 
activity induces an elevated response to chemotherapy. This supports our hypothesis, that 
enhanced APC activity reverses MDR behaviour. 
 These viability assays demonstrate that enhancing APC activity results in a reversal of 
MDR behaviour, as chemosensitivity was enhanced upon peptide expression. Both peptides 
elevated indirect APC activity, and the peptide that induced the greatest elevation in APC activity 
provoked the greatest augmentation of chemosensitivity. Together, this suggests an APC activity 
specific relationship between APC E3 function and MDR behaviour. This strongly supports the 
validity of our initial hypothesis, that enhancing APC activity can result in reversal of MDR 



































Figure 4.5. Increased APC activity correlates with increases in MDR breast 
cancer chemosensitivity. Changes in cellular viability due to peptide expression were 
measured using chemosensitivity assays using DOX as the cytotoxic agent and MTT 
as the reporter assay. A) 6-well chemosensitivity assays utilizing 1μM of DOX for 48 
hours. Unpaired t-tests comparing individual peptide expressing lines to the control (a 
231-cell line stably transfected with an empty pcDNA vector) were performed to 
establish statistical significance, n=9 technical repeats; *=p<0.05, error bars represent 
SEM. B) 96-well chemosensitivity dose-response assay ranging over DOX 
concentrations of 0 μM to 1 μM over 48 hours. n=10 technical repeats; error bars 
represent SEM. C) 95% confidence intervals over the dose response curve, generated 







 Due to previous observations correlating APC dysfunction with chemotherapy 
resistance/MDR behavior (Arnason unpublished), we hypothesized that enhancing APC activity 
will restore chemosensitivity in MDR cancer. Our novel approach to enhancing APC activity was 
to adapt APC-binding and -activating peptides discovered in yeast, into peptides capable of 
expression in human cell lines by cloning into human expression vectors. The yeast APC-
activating peptides were discovered through 2-hybrid protein-protein interactions between APC 
subunits and a random peptide library, and were shown to be able to augment several discrete APC 
functions in yeast, including stress response pathways and longevity pathways These are well 
known APC function in yeast and easily assayed. Due to evolutionary conservation of the APC 
structure and function between S. cerevisiae and human, the peptides were predicted to also be 
able to activate the human APC. Longevity and stress pathway assessment in human cell lines are 
not established means of determining human APC activity, and instead we relied on indirect 
measures of APC E3-ligase activity, by monitoring target protein degradation. 
 To establish the optimal method of enhancing APC activity through peptide expression, 
each peptide of interest from our yeast studies was cloned into the expression vector pcDNA as 
one of two versions, either with an N-terminal NLS, or without (Figure 4.1). When tested for 
protein target degradation, peptide versions with the NLS unexpectedly reduced APC activity 
relative to their non-NLS counterpart (Figure 4.2). While we do not have a clear explanation for 
the loss of activity, it may be due to the NLS and B42 sequences inhibiting the binding capabilities 
of the peptides to the APC, possible arising because of the larger size of the protein backbone 
containing the NLS (22.48 kDa) versus, the backbone without the NLS (8.86 kDa). The additional 
amino acids in the NLS backbone may physically block the peptides from binding the APC. As 
part its regular function TrxA localizes to the nucleus, and this self-localization may assist TrxA-
peptide localization, however this is unlikely a critical mechanism of peptide functioning. During 
previous research, commercially produced TAT2-peptide-FITC conjugates (University of Alberta, 
Edmonton AB, Canada) with no TrxA backbone have been synthesized. TAT2 (Trans-activating 
transcriptional activator 2) is a cell penetrating peptide derived from HIV, and upon conjugation 
with secondary molecules has been utilized as a drug delivery system (Mishra et al., 2011). 
Fluorescein isothiocyanate (FITC) is a fluorescent molecule detectable through fluorescence 
microscopy (Chaganti et al., 2018). After exogenously applying the TAT2-peptide-FITC 
conjugates to cancer cells, fluorescence of FITC indicated localization of the conjugates to the 
nucleus, therefore the peptides appear capable of self-localization to the nucleus without additional 
protein backbone (data unpublished).    
 Of the seven tested peptides (as depicted in Table 4.1), two (C13.3 and C43.4) 
demonstrated consistent elevation in APC activity across all three tested substrates (Figure 4.3). 
These were also two of only three peptides that did not contain a premature stop codon. Having 
two bounding thioredoxin domains surrounding the short peptide sequences may assist in peptide 
efficacy by having both peptide ends tethered and confined, providing a defined 3-dimentional 
structure to the peptide. This may produce a more effective conformation, rather than having a free 
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untethered C-terminus. Alternatively, it may be that the presence of the C-terminal region of 
thioredoxin provides a more stable protein hybrid product that is not rapidly degraded. In vitro 
studies with the exogenous application of C43.4 through the TAT2-C43.4-FITC conjugate 
demonstrated an ability to enhance chemosensitivity, indicating nuclear localization to activate the 
APC (data unpublished). The TrxA backbone, therefore, may not be essential to peptide function, 
however there is a noted difference in abundance between these approaches, namely exogenous 
application of a set quantity of peptide, versus continual endogenous expression.  
 Unfortunately, we were unable to verify the expression of any of the peptides after their 
stable transfection into the 231 cells (Figure 4.3). Despite this, there are clear biological 
differences noted in 231 cells and behavioural alterations arising from C13.3 and C43.4 expression 
compared to the empty vector control cells indicating they are likely expressed, despite the lack of 
confirmed expression by Western blot. Nonetheless, the purpose of experimenting with seven 
peptides was to identify the peptides most effective at elevating APC activity.  
 We do not currently know the mechanism by which the peptides elevate APC activity in 
mammalian cells, whether they behave similarly to each other, or have different mechanisms of 
action. They may act in identical ways just with different potencies, or their differences may reflect 
unique processes affecting APC function. We suspect the peptides directly bind specific APC 
subunits in human cells, in a similar manner to the yeast 2-hybrid global screen (data unpublished). 
This yeast screen found C43.4 through its binding to APC10, whereas C13.3 was identified though 
its binding to APC5 (Table 4.1). While both APC5 and APC10 subunits have highly conserved 
orthologs in human cells, we have yet to establish this direct physical interaction in mammalian 
cells.  
 Multiple potential mechanisms exist through which the peptides likely enhance APC 
activity, and given the discrete subunits bound by C43.4 and C13.3 in yeast, the specific 
mechanisms are likely distinct. As the APC is a multi-subunit complex, the interactions between 
subunits is a critical component for maintaining complex stability and therefore activity. APC5 
plays a structural role in maintaining complex cohesiveness, and its degradation results in APC 
complex dissociation and loss of function (Chang et al., 2014). Therefore, C13.3 may allosterically 
promote complex stability through binding to APC5, and therefore activity. APC5 also experiences 
numerous post-transcriptional events including phosphorylation, and ubiquitination sites (many 
with undefined functions) (Tran et al., 2010; Zhang et al., 2016). Therefore, binding of C13.3 to 
APC5 may also block inhibitory post-transcriptional modifications including inhibitory 
phosphorylation events or polyubiquitination (protecting from subsequent proteasomal 
degradation). APC10 does not experience significant post-transcriptional modifications (Zhang et 
al., 2016) therefore, blocking post-transcriptional modifications is less likely to contribute to the 
elevated activity. APC10 functions to facilitate substrate recognition, and resides inside the 
binding pocket (Chang et al., 2014). It remains possible that C43.4 enhances substrate recognition 
through APC10 associations. This could be achieved through allosterically altering the 
conformation of the binding pocket to permit more efficient substrate binding. These described 
mechanisms are based on the assumption that the peptides elevate the efficiency at which their 
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bound subunits perform their known functions. However, until further investigations are carried 
out to specifically investigating these mechanisms, the exact manner remains unknown. 
 The altered abundance of APC regulatory proteins which are also targeted for degradation 
(including those not characterized in this study, notably PLK1 (Zhang et al., 2014) and CDH1 
[Visintin et al., 1997]) induced by peptide expression may also contribute to altered APC activity. 
The initial degradation of these regulatory proteins upon peptide activation of APC by peptide 
expression may create a feedback mechanism that modulates APC activity. The possible 
conclusions drawn from these decreased abundances of the APC activators Cyclin B1 and CDC20 
(Figure 4.4) are tentative, but noteworthy. The degradation of Cyclin B1 is necessary for the 
binding of CDH1 to the APC (Kraft et al., 2003; Kramer et al., 2000), and therefore its elevated 
degradation is likely promoting the transition of APC activity between CDC20 and CDH1. This is 
supported by the degradation of CDC20, as it is solely performed by APCCDH1 (Zhang et al., 2014), 
indicating that the peptides are elevating APCCDH1 activity. The degradation of CDC20 may 
prevent oncogenic behaviour, as CDC20 accumulation is a noted oncogenic behaviour (Chang et 
al., 2012; Ding et al., 2017; Ding et al., 2014; Mao et al., 2016; Wu et al., 2013). However, as will 
be presented in Figure 5.2, NEK2A experiences elevated degradation from C13.3 but not C43.4 
expression. As NEK2A is exclusively degraded by APCCDC20 (Zhang et al., 2014), this indicates 
that APCCDC20 does experience an elevation in activity. The lack of C43.4 elevated degradation of 
NEK2A does not necessarily indicate that C43.4 does not promote APCCDC20 activity, simply that 
it was not observed in this target. 
 The experiments presented here demonstrate that enhanced APC activity resulted in 
restoration of chemosensitivity, as shown by elevated cell killing of MDR cells in response to 
chemotherapy. Furthermore, the degree of restored chemosensitivity was in a manner proportional 
to the extent of APC activation (Figure 4.5 A-C).   
 It is notable that C13.3 and C43.4 contain sequence homologies to multiple proteins of 
interest despite their short sequences of 20 amino acids each. Several proteins have known 
biological functions that make the homology very interesting, and could be used to rationalized, 
in part, their ability to activate APC. Notably, when the peptide sequences were BLASTED for 
amino acid alignment again the yeast protein database, peptide C43.4 contains homology to the 
histone variant Htz1 and peptide C13.3 contains homology to Apc1, a critical subunit that is 
heavily post-translationally modified to regulate APC complex activity (Zhang et al., 2016; data 
unpublished). General grouping of yeast proteins with homology to the peptides includes 
biological functions in proteasomal, stress response/metabolism, and DNA-chromosome 
interactions. The peptides were similarly BLASTED against human proteins, and identified several 
proteins that are known to have a diverse array of functions that may be potentially relevant to 
APC activity, and again demonstrate APC1 subunit similarity for peptide C13.3 (Table 4.2). The 
homologies between the peptides and these proteins may indicate as yet undiscovered interactions 
of the APC in yeast and their orthologues in mammalian systems.  
 Our observations that enhanced APC activity restores a degree of chemosensitivity leads 
to the question of the usefulness of this approach in cancer therapy. In vitro studies of cancer cell 
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responses when the APC was chemically inhibited and induced a severe toxic effect in healthy 
cells due to the suppression of APCs’ essential functions (Zhang et al., 2014). Here, our activation 
of the APC through peptide expression did not induce a toxic effect until paired with 
chemotherapy. The viability of cells exposed only to peptide expression was not significantly 
lower than baseline cellular viability, indicating that the peptides did not appear to produce an 
innately toxic effect. Others in the lab have confirmed this nontoxic effect of the peptides on whole 
animals (intraperitoneal peptide infusions into female mice), or when APC was stimulated using 
commercial APC activators (MAD2 inhibitors) in vitro. This supports the safety and usefulness of 
the APC activation approach for future cancer therapeutic studies as healthy cells may be relatively 
unaffected by the peptide treatment.  
 When considering the usefulness of these peptides for direct cancer therapy, there are 
several potential issues and limitations unique to protein and peptide therapies. In in vivo models, 
the exogenous application of peptide-conjugates may induce an immunological response and 
prevent effective treatment. Also, the proteins may not have a sufficiently long half-life to confer 
a meaningful serum concentration, or there may be a failure to correctly target the malignancies at 
therapeutic concentrations. Our experiments utilized endogenous expression of the peptides which 
would be impractical in a patient. Despite these obvious concerns, the TAT2-C43.4-FITC peptide 
conjugate has demonstrated an in vitro capability to induce chemosensitivity in a similar manner 
to our observations. Furthermore, Gabby Mercer (MSc candidate) in our lab has successfully 
xenografted C13.3 and C43.4 expressing 231 cells in vivo in mice. Significantly, the tumors 
demonstrated a dose-dependent inhibition of tumor growth over a 21-day experiment after a single 
intraperitoneal peptide dose, indicating that the peptides promote anti-tumorigenic effects in vivo. 
If necessary, to circumvent the issues related to protein-based therapies, after establishing the exact 
mechanism of peptide action on the APC, pharmacological mimetics of the peptides could be 
identified and synthesized. Despite these challenges, the principle of enhancing APC activity as a 
therapeutic model remains a promising option for cancer treatment.  
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5.1.1 Multiple drug resistance (MDR) behaviour and the APC 
 During cancer development and progression, the individual cancer cells experience 
alterations to their behaviour including metastasis, altered proliferative patterns, and acquire MDR. 
Based on selective pressures, these behaviours may become adopted throughout the population 
(Gerlinger et al., 2012). MDR behaviour is characterized as the resistance of the cancer population 
to multiple, mechanistically unrelated therapies including those not used for treatment (Holohan 
et al., 2013; Housman et al,.2014). MDR behaviour arises through impaired apoptosis, stress 
response pathways, dysregulated mitosis, and genomic instability (Austin Doyle et al., 1998; Choi 
2005; Fernald and Kurokawa, 2013; Lee et al., 2011; Miyashita and Reed, 1993; Zhu et al., 2014). 
Proper functioning of the APC promotes the activation of stress responses, and promotes a 
regulated mitotic cycle, thereby combating multiple mechanisms of MDR behaviour. To 
investigate the link between APC dysfunction and MDR development, a series of novel peptides 
were identified in a yeast 2-hybrid library as being capable of binding and enhancing APC activity. 
Upon subcloning of these peptides into mammalian expression vectors, they were stably 
transfected into the innately MDR breast cancer cell line 231. Two peptides were identified that 
both promoted enhanced APC activity and cytotoxic sensitivity of the cells to the 
chemotherapeutic agent DOX (Figure 4.4 & 4.5). Here we will investigate the mechanistic 
underpinnings reversing MDR behaviour upon enhancement of APC activity.  
 
5.1.1 Mitosis and genomic instability 
 The APC is named for its first recognized biological function, that of promoting the 
regulated progression of mitosis, specifically through mitosis into anaphase. It has been long 
recognized that the APC and the associated SAC are required to be functional to prevent cells 
harboring DNA damage or chromosomal defects from passing through this cell cycle stage and 
expanding through division. Cancer is well known to arise due to mutations and chromosomal 
defects, and impairments in APC function is known to correlated with cancer development. 
Furthermore, more aggressive cancers (e.g., treatment resistant or metastatic) appear to correlate 
with greater degrees of APC dysfunction. This has been observed indirectly through the 
accumulation of APC substrates in malignant compared to benign tumors (Lehman et al., 2007). 
A gene network has also been identified whose expression is correlated with an elevated 
expression of CDC20 including APC regulators and substrates, indicating generalized APC 
dysfunction during cancer progression (Zhang 2019). There has also been an association in canine 




 The specific role that APC plays in controlling mitotic progression and promoting genomic 
integrity has been the focus of multiple studies and has revealed elegant molecular mechanisms 
involved in coordinating the cell cycle with quality checks, as well highlighting the defects that 
arise when APC is dysfunctional (Visintin et al., 1997, Kramer et al., 2000; Izawa et al., 2015; 
Cappell 2018; Garcí-Higuera et al., 2008; Sivakumar 2015). If we consider the initiation of mitosis 
as our starting point to discuss the role of APC activity within the cell cycle, then even prior to 
chromosomal alignment during metaphase there are key regulatory steps occurring. Here, the APC 
is inhibited by the SAC through sequestration of the APC co-activator CDC20 (Pan and Chen, 
2004). Upon chromosomal attachment to microtubules the SAC releases CDC20 permitting its 
binding to the APC and forming the active APCCDC20 complex. The APC then functions through 
its Ub-ligase function to target and degrade key proteins to enable regulated chromosomal 
segregation. One of the first proteins targeted for polyubiquitination by APCCDC20 is Securin, 
triggering its proteasomal degradation, and allowing for chromatin separation to their respective 
poles. Specifically, Securin allosterically inhibits the protein Separase, which cleaves the kleisin 
subunit of cohesin, which holds sister chromatids together (Gligoris et al., 2014; Lin et al., 2016). 
The APC simultaneously targets Cyclin B1 for gradual degradation which ultimately results in the 
replacement of the co-activator CDC20 (APCCDC20) with CDH1 (APCCDH1) in coordination with 
the cell cycle, until only APCCDH1 remains it is and this complex that functions throughout mitotic 
exit and G1 (Castro et al., 2005; Kramer et al., 2000; Visintin et al., 1997). Specifically, 
degradation of Cyclin B1 prevents CDK1 from placing the inhibitory phosphorylation onto CDH1 
which would normally inhibits CDH1 binding and incorporation into the APC complex. Therefore, 
after Cyclin B1 degradation by APCCDC20, CDH1 gradually replaces CDC20 to form APCCDH1, 
initiating the second phase of APC activity. During mitosis, the early primary role of APCCDH1 
consists of preparing the cell for a regulated mitotic exit, again through substrate degradation 
(Kramer et al., 2000; Visintin et al., 1997). 
 There are several points where APC dysfunction could contribute to new cancer 
development or progression into more aggressive forms. A dysregulated mitosis is one of the 
principle mechanisms leading to the chromosomal instability that occurs in cancer cells, and is a 
primary driver of cancer progression (Crasta et al., 2012; Gerlinger et al., 2012; Lee et al., 2011; 
Ohashi et al., 2015; Zhu et al., 2014). Due to the sustained chromosomal instability during cancer 
development, cancer cells often experience sustained SAC activity, as chromosomes fail to 
properly align during metaphase. This prolonged SAC activity, is referred to as mitotic arrest 
(Dalton et al., 2007; Quignon et al., 2007). In healthy cells, mitotic arrest typically resolves as 
chromosomes eventually successfully align, in which case the SAC becomes inactivated and the 
cell progresses through mitosis due to normal APC activity. Alternatively, prolonged mitotic arrest 
can instead result in apoptosis (Riffell et al., 2009). Interestingly, in cancer cells a third outcome 
of prolonged SAC activation is mitotic slippage where cancer cells override SAC inhibition and 
the cell (inappropriately) progresses through mitosis (Bonaiuti et al., 2018; Jiang et al., 2003; Toda 
et al., 2012; Park et al., 2018). Consequences of mitotic slippage include dysregulated cell 
proliferation, chromosomal mis-segregation, resistance to microtubule poisons, and accumulation 
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of generalized DNA damage (Anand et al., 2003; Crasta et al., 2012; Jiang et al., 2003; Riffell et 
al., 2009; Ohashi et al., 2015; Sudo et al., 2004; Zhu et al., 2014).  
 There are multiple mechanisms through which cancer cells can induce mitotic slippage. 
First is the over-accumulation of CDC20 which may arise through its overexpression or impaired 
degradation. The overabundance of CDC20 overrides SAC activity, as the SAC lacks the capacity 
to sufficiently sequester the excess CDC20 protein, and the APC becomes activated despite 
continued chromosomal misalignment (Bonaiuti et al, 2018; Pan and Chen, 2004). Mitotic 
slippage can also be induced by the second coactivator CDH1. ATP depletion during a prolonged 
mitotic arrest results in the loss of inhibitory phosphorylation on CDH1, permitting its binding to 
the APC before CDC20, and inducing chromosomal segregation (Nagai et al., 2014; Park et al., 
2018; Toda et al., 2012,).  
 
5.1.2 Stress response pathways 
  The impairment of stress response pathways by cancer is multi-faceted and provides 
advantages to tumor growth and survival through the inhibition of apoptosis, and promotion of 
proliferative pathways (Fernald and Kurokawa, 2013; Gardai et al., 2004; Kinoshita et al., 1997; 
Vander Heiden and DeBerardinis, 2017). Yeast and mammalian studies have identified conserved 
stress response networks that experience frequent alterations in cancer, and multiple interactions 
have been identified between the APC and these pathways. In yeast, genetic interactions between 
the APC and Forkhead 1 and 2 (orthologues to mammalian FOXO transcription factors) 
highlighted their intersecting role in inducing stress responses and resultant apoptosis (Malo et al., 
2016; Postnikoff et al., 2012). FOXO proteins are a family of transcription factors that intensify 
stress responses through expression of key genes/proteins, including Death Receptor 4/5, p27Kip1, 
Bim, and Bcl-6 (Greer and Brunet, 2005; Roy et al., 2010; Shoeb et al., 2013). The elevation of 
FOXO activity (particularly FOXO3A) in cancer has demonstrated anti-tumorigenic effects and 
induces apoptosis in vitro (Dey et al., 2015; Roy et al., 2010; Shoeb et al., 2013; Thayyullathil et 
al., 2011). In mammalian systems, the FOXO family is regulated through AKT phosphor-
signaling, which is a downstream effector of multiple growth factor stimulated pathways (Pros et 
al.,2013). In response to nutrient sensing and growth factor signaling, AKT activity is promoted 
by the PI3K pathway and inhibits stress responses while promoting cell proliferation through its 
phosphorylation of multiple proteins including the transcription factor FOXO3A (Brunet et al., 
1999). Accordingly, activation of FOXO3A through the inhibition of AKT has demonstrated 
therapeutic efficacy in cancer cytotoxicity (Dey et al., 2015; Roy et al., 2010; Shoeb et al., 2013; 
Thayyullathil et al., 2011). AKT activity is also directly associated with MDR behavior in 
malignant cells, and is specifically associated with an elevated abundance of the MDR makers, 
MDR-1 and MRP, members of the ABC drug efflux transporter family (Zhou et al., 2013). AKT 
activity also promotes the vesicle mediated transport of the ABC transport protein BCRP for 
surface expression (Goler-Baron et al., 2008). The inhibition of AKT has demonstrated therapeutic 
potential, overcoming MDR behaviour, inducing cell arrest and apoptosis, and is under clinical 
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investigation for therapeutic potential in cancer treatment with multiple AKT inhibitors in clinical 
and preclinical trials (Bartholomeusz et al., 2012; Konopleva et al., 2014).  
 AKT is endogenously negatively regulated through protein phosphatase 1 (PPP1) which 
acts as a tumor suppressor protein. PPP1 dephosphorylates the activating (phospho)-sites on AKT 
to inhibit its activity (Thayyullathil et al., 2011). PPP1 itself is regulated by phosphorylation 
through multiple proteins including the mitotic kinase NEK2A (Helps et al., 2000; Rellos at al., 
2007,), and the cyclin dependent kinases CDK1 and CDK2. (Blethrow et al., 2008; Guo et al., 
2002). CDK1 activation is driven by Cyclin B1 during G2 and M to promote mitotic initiation and 
progression, and CDK2 is driven by Cyclin A2 to promote the G1/S and G2/M cell cycle 
transitions. 
 
Figure 5.1. Schematic of the cellular pathway connecting APC E3 activity to the 
activation of stress response pathways. The APC substrates Cyclin A2, Cyclin B1, 
and NEK2A are inhibitors of stress responses through inhibition of PPP1 activity. Each 
substrate performs an inhibitory phosphorylation on residue T320 of protein 
phosphatase 1-alpha catalytic subunit (PPP1CA, Blethrow et al., 2000; Guo et 
al.,2002; Helps et al., 2000; Rellos et al., 2007) to inhibit PPP1 activity. PPP1 is then 
prevented from dephosphorylating AKT1 at sites Threonine450 (T450) and Serine473 
(S473), promoting AKT1 activation (Thayyullathil et al., 2011). Active AKT1 
performs inhibitory phosphorylation on Serine253 (S253) of FOXO3A (Brunet et al., 
1999). Elevated degradation of the APC protein substrates Cyclin B1, Cyclin A2, and 
NEK2A would hypothetically reduce the inhibition of PPP1, triggering 
dephosphorylation of AKT1 to permit FOXO3A activity and enhance stress response 
and apoptotic pathways. Pointed arrows represent activation of the downstream 
proteins, blunt arrows represent inhibition of the downstream proteins.  
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5.2 Materials and Methods 
 
5.2.1 Cell Culture 
 The protocol was previously described in section 3.2. 
 
5.2.2 Western Blotting 
 The protocol was previously described in section 3.3. In 231 cell lines, we assessed relative 
apoptosis rates by measuring Poly (ADP-ribose) polymerase (PARP) cleavage, after inducing 
cytotoxic stress via incubation in the presence of either 0.5 μM or 1.0 μM doxorubicin (DOX) for 
48 hours prior to cell lysis. To determine general DNA damage abundance, histone H2A 
phosphorylation (γH2A.X) was measured. Cells were passaged for 1 month prior to lysis to permit 
observable alterations to DNA damage and accumulation. 
 
5.2.3 Fluorescence Microscopy of DNA and Mitotic Figures 
 The protocol was previously described in section 3.5. Asynchronous 231 cells were fixed 
in 4% paraformaldehyde for 10 minutes before permeabilization with 0.5% Triton X-100 for 10 
minutes. Cells were then stained with the nuclear stain 4′,6-diamidino-2-phenylindole (DAPI) and 
visualized using fluorescence microscopy. Criteria for mitotic catastrophe includes visible failure 
to properly align chromosomes during metaphase, lagging chromosomes during anaphase, 
micronuclei formation, and asymmetric nuclei formation. A minimum of 250 cells were sampled 
for each population for each repeat.  
 
5.2.4 Kinome Array  
 This protocol was previously described in section 3.6, and the array itself was performed 
by collaborators in the Dr. Napper lab (University of Saskatchewan), whereas the analysis and 
pathway construction was performed by us. The kinome array was performed as previously 
described (Määttanen et al., 2013). Briefly, it involved immobilized pre-selected peptides known 
to be phosphorylated by discrete kinases. Using cell lysates prepared from treated cell lines (our 
control [empty pcDNA], C13.3, and C43.4 cell lines) and applying them to the peptide array allows 
for phosphorylation to occur where possible, and quantitation to be performed. The kinome array 
was constructed to investigate a wide range of peptide targets from multiple signaling pathways to 
reflect many cellular behaviours. Changes in phosphorylation between the control cell line and the 
peptide cell lines greater than +/- 1.5-fold change (FC) were considered significant. Note that this 
is a smaller difference than that considered significant for gene expression arrays where +/- 2 FC 
is often the cut off for significance differences. Changes in phosphorylation between the control 
cell line and the peptide cell lines between +/- 1.2 and 1.5-fold were considered moderate changes. 
The associated pathways established from the kinome data were assembled with assistance from 




5.2.5 Statistical Analysis 
 The protocol for unpaired t-testing as performed in western blotting and imaging 
experiments was previously described in section 3.2.5. Statistical analysis for the kinome array 
was performed as described previously (Määttanen et al., 2013). Briefly, a chi-square test 
examined technical variability and phosphorylation sites with variability above an acceptable 
threshold (as determined by the chi-square test) were excluded from further analysis. T-tests were 
then performed for each phosphorylation site/peptide target between the control and APC-
activating-peptide expressing samples. As the chi-square test has already screened for technical 




5.3.1 Assessment of the AKT-FOXO Stress response pathway as a result of altered APC 
activity 
 Guided by previous studies demonstrating the genetic interactions between the APC and 
yeast Fkh proteins to induce stress responses (Malo et al., 2016; Postnikoff et al., 2012), the impact 
of enhanced APC activity on the evolutionarily conserved activating FOXO protein 
phosphorylation signal was examined. To investigate the role of augmented APC activity in 
regulating the AKT/FOXO3A pathway, two 20-amino acid novel peptides (dubbed C13.3 and 
C43.4), that were previously established to enhance APC activity (Figure 4.4) were cloned into a 
mammalian expression vector and stably transfected into the innately MDR cell line, MDA-MB-
231 (referred to as 231). To explore the pathway(s) connecting APC activity to FOXO3A 
activation, three degradation substrates of the APC known to interact with the AKT-FOXO3A 
pathway were examined for their stability as APC activity was manipulated. The substrates 
analysed included Cyclin A2, Cyclin B1, and NEK2A (Figure 5.1), and we observed that there 
were variable degrees of enhanced target protein degradation upon peptide expression. C43.4 
reduced Cyclin B1 abundance to 49.9% (p<0.0001), and Cyclin A2 to 70.6% (p=0.3625) of the 
control, while failing to noticeably reduce NEK2A accumulation (Figure 4.3 A, D and Figure 
5.2). C13.3 reduced Cyclin B1 abundance to 73.9% (p<0.0001) and NEK2A abundance to 67.3% 
(p= 0.1208) of the control, while failing to reduce Cyclin A2 levels (Figure 4.3 A, D and Figure 
5.2). The variability in substrate degradation between the peptides highlights that the augmented 






Figure 5.2. Enhanced APC activity increases degradation of APC substrates 
known to inhibit FOXO3A signaling and stress responses. A) Qualitative 
representative Western blots of the APC protein substrates NEK2A and Cyclin A2. 
Quantitative representation of B) Cyclin A2, C) NEK2A, protein abundance is 
adjusted to the actin load control, then normalized to the control value of 1.0 (231 cell 
line stably transfected with an empty pcDNA vector. n=3 biological repeats. Unpaired 
t-tests between control and individual peptides were performed to establish statistical 
significance; Error bars represent SEM. 
 
 We predicted that the observed decrease in FOXO3A inhibitory proteins upon APC 
activation would result in increased pathway activity. The impact on the signalling activity of the 
AKT/FOXO3A pathway was directly tested by searching for altered phosphorylation levels of 
three key regulatory phospho-targets within the stress response pathway, both increases and 
decreases depending on whether they were activating or inhibitory modifications.  
 The impact of peptide C43.4 (and presumably the activation of the APC) on the inhibitory 
p-PPP1CA T320 was to reduce the signal to 68.6% (p=0.0583, Figure 5.3 A, B) indicating 
increased activity of PPP1α and subsequent activation of the FOXO-mediated stress pathways. p-
AKT1 S473 abundance was also modestly reduced to 83.9% (p=0.0749, Figure 5.3 A, C) 
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indicating a mild reduction in activity demonstrated by a consistent reduction in phospho-protein, 
rather than the magnitude of the change. Phosphorylation of FOXO3A at S253 was reduced to 
54.6% (p=0.0028) of control (Figure 5.3 A, D), indicating a significant elevation in FOXO 
activation. This demonstrates that C43.4 appears capable of inducing stress response pathways 
through the activation of FOXO3A transcriptional activity, presumably through enhanced APC 
activity.  
 p-PPP1CA T320 was reduced by C13.3. expression to 65.4% (p=0.0284) indicating an 
elevation in PPP1α activity. Notably, p-AKT1 S473 was different for the C13.3. peptide, as it was 
elevated to 226% (p=0.1535) of the control. Despite the apparent elevation in AKT1 signaling 
(and the expectation of FOXO repression resulting therein), p-FOXO3A S253 was also reduced 
58.8% (p=0.0031) by C13.3, and to a similar extent to that observed for C43.4 (Figure 5.3 A, D). 
Together, this suggests that both C43.4 and C13.3 expression are capable of elevating FOXO3A 
































Figure 5.3. Enhanced APC activity promotes stress responses through FOXO3A 
signalling. A) Qualitative representative Western blots of the stress response pathway 
relating APC activity to the AKT-FOXO3A signaling pathway. Quantitative 
representation of B) p-PPP1CA (T320), C) AKT1 (S473), D) p-FOXO3A (T320), E) 
p-AKT (S473), F) and p-FOXO3A (S253). Phospho-protein abundance is adjusted to 
total protein and Tubulin load control, then normalized to the control value of 1.0 (231 
cell line stably transfected with an empty pcDNA vector n=3 biological repeats. 
Unpaired t-tests between control and individual peptides were performed to establish 







 We also considered how to assess for changes in nutrient and energy signalling pathways 
in response to APC activity (via peptide expression), as these pathways are well established to also 
converge on FOXO to modify its activity downwards (rich nutrients inhibits stress signaling and 
apoptosis) or upwards (energy depletion augments stress response pathways and promotes cell 
survival and longevity) (Greer and Brunet, 2005). Cell culture conditions are designed to support 
optimal cell growth by providing excess nutrients and energy. Therefore, cellular networks would 
be shifted to suppress stress responses and apoptosis, and instead promote proliferation. We were 
therefore interested to determine the effect that stressful growth conditions would have on our 231 
MDR breast cancer cells, and the impact that APC activation would make to the pathway balance.  
 Low glucose media (1000 mg/L D-glucose compared to the 4500 mg/L D-glucose in 
standard media) was used as a means of mimicking combined nutrient and energy starvation. To 
examine the effect of enhanced APC activity on stress response networks in response to metabolic 
stresses 231, cells were cultured in low glucose media for 5 days. Using these nutrient/energy 
stress conditions, we observed significant reductions in the inhibitory FOXO3A phosphorylation 
site at S253 with both peptides. When compared to the control (empty pcDNA), peptide C13.3 
reduced this phosphorylation to 39.9% (p=0.0295) and C43.4 reduced this phosphorylation to 
43.8% (p=0.0063, Figure 5.4). The elevation in FOXO3A activity upon peptide expression under 
low glucose conditions is a more significant enhancement than that observed under standard “rich” 
growth conditions (Figure 5.3 A, D). This indicates that enhancing APC activity elevates the stress 
responses of MDR cancers to both cytotoxic and noncytotoxic stresses and may contribute to their 














Figure 5.4. Enhancing APC activity sensitizes the cell to metabolic stresses by 
promoting FOXO3A activity. 231 cells were cultured in low glucose media for 5 
days to induce a stress response through energy deprivation. A) Qualitative 
representative Western blot of total FOXO3A and phopshorylated-FOXO3A 
(Serine253) from whole cell lysates after the energy stress. B) Quantitative 
representation of p-FOXO3A protein abundance adjusted for the GAPDH load control 
and normalized to the control (231 cell line stably transfected with an empty pcDNA 
vector), set to 1.00. n=3 biological repeats. Unpaired t-tests between control and 
individual peptides were performed to establish statistical significance; *=p<0.05, 
**=p<0.01. Error bars represent SEM. 
 
 Common biomarkers of MDR cancer behaviour are the elevated abundance of several 
members of the ABC transport protein family including BCRP, MDR-1, and MRP-1. These 
proteins act as non-specific drug efflux pumps, protecting cancer cells from chemo- and molecular 
therapies (Choi, 2005). Driven by NEK2A activity, AKT promotes the expression of multiple ABC 
transporters through AKT’s downstream targets, including both PIM1 and NFκB proteins (Zhou 
et al., 2013). AKT also directly promotes the vesicle mediated transport of BCRP to the cell surface 
to promote drug efflux (Goler-Baron et al., 2008). Therefore, the observed alterations in NEK2A 
abundance (Figure 5.2 A, C) and AKT activity (Figure 5.3 A, C) driven by enhanced APC activity 
may decrease ABC transporter abundance and reverse MDR behaviour. C43.4 reduced BCRP 
abundance to 76.1% (p=0.1824) and MDR-1 to 82.0% (p=0.1791) of control (Figure 5.5). C13.3 
was unable to significantly alter BCRP levels and elevated MDR-1 to 149% (p=0.2388) of the 
control, although inconsistency in the C13.3 lysates prevents this from being a conclusive elevation 
(Figure 5.5). As the reductions in MDR marker abundance from C43.4 are not statistically 
significant, nor the observed change in protein accumulation large, it is difficult to draw a 
conclusion to the biological relevance of this apparent alteration. If these reductions induced a 
biological impact it could contribute to the enhanced chemosensitivity seen in C43.4 expressing 
231 cells (Figure 4.5). The potential ability for C43.4 to reduce ABC transporter abundance 
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supports the idea that C43.4 is impairing AKT1 activity (Figure 5.3 A, C) and thereby causing 
alterations in cellular behaviours.   
 
Figure 5.5. Enhancing APC activity potentially lowers the abundance of classic 
MDR protein biomarkers, BCRP and MDR-1. A) Qualitative representative 
western blot of BCRP and MDR-1 from whole cell 231 lysates. Quantitative 
representative Western blot of B) BCRP and C) MDR-1. Quantitative representation 
of B) BCRP, and C) MDR-1 protein abundance adjusted for the tubulin load control 
and normalized to the control (231 cell line stably transfected with an empty pcDNA 
vector), set to 1.00. n=3 biological repeats. Unpaired t-tests between control and 
individual peptides were performed to establish statistical significance. Error bars 
represent SEM. 
 
5.3.2 Enhanced APC activity promotes apoptosis 
 We investigated if the observed changes in the activity of the stress response pathway upon 
APC activation pathways resulted in a shift in the balance between apoptosis versus cellular 
proliferation in our MDR breast cancer cell populations, as fully activated stress pathways do 
promote the fidelity of cellular checkpoints and result in apoptosis of damaged cells (DeBardinis 
et al., 2008; Gong et al., 2018). Our previous observation that APC activation restored 
chemosensitivity/cell death in our inherently MDR cell line suggested to us that the altered 
FOXO3A phosphorylation may ultimately demonstrate increased apoptosis. To detect apoptosis, 
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multiple complementary markers were investigated under both cytotoxic and non-cytotoxic 
conditions.  
 First, to examine the capability of the cytotoxic chemotherapy agent DOX to induce 
apoptosis in MDR cells with or without enhanced APC activity, 231 cells were exposed to 0.5 μM 
and 1.0 μM concentrations of DOX for 48 hours. The relative abundance of the apoptotic marker 
PARP (and its respective cleavage products) was done through western blotting. PARP protein 
undergoes predictable cleavage events during apoptosis initiation, generating a 89 kDa and a 24 
kDa fragment (Nicholson et al., 1995). At 0.5 μM, we were unable to detect PARP cleavage. This 
suggests that at lower concentrations of DOX, the observed decrease in cellular viability (Figure 
4.5) may be a result of cells beginning apoptosis, but not completing the process. At 1.0 μM PARP 
cleavage (cPARP) products were detected with expression of both peptides. We have previously 
noted that MDR cancer cells experience an enhanced cell death response to chemotherapy upon 
peptide-induced APC activation, and this experiment suggests that the cell death in MDR cancer 
is through promotion of apoptotic pathways.  
 Second, apoptotic pathway biomarkers, Caspase 8 and 3 activity, were investigated in the 
231 cells with and without peptide activation of the APC. We used a caspase reporter kit capable 
of simultaneously measuring both (Abcam). Caspase 8 activity is indicative of early activation of 
the extrinsic apoptotic pathway (Olsson and Zhivotovsky, 2011), whereas Caspase 3 activity is 
indicative of later stages when the cell is completing apoptosis, and is activated by both the 
intrinsic and extrinsic apoptotic pathways (Olsson and Zhivotovsky, 2011). The reporter kit 
provides a more sensitive measure of apoptotic activity than western blotting for PARP; however, 
the caspase kit was unsuitable for examination of apoptosis after DOX treatments, as there is no 
method of equilibrating surviving cell numbers between the different sample treatments that differs 
due to peptide expression, whereas surviving cell numbers can be adjusted through lysate loads 
prior to western blotting.  
 Expression of both C13.3 and C43.4 were pro-apoptotic in the 231 cell lines as compared 
to control when examined at the 1.0 μM DOX dose, with C43.4 providing the more significant 
elevation (Figure 5.6 A-C). This correlates with C43.4 inducing the more significant enhancement 
in chemosensitivity (Figure 4.5), indicating that inducing apoptosis is likely the main mechanism 
driving the reversal of MDR behaviour. The activity of caspases 3 and 8 was also elevated upon 
peptide expression demonstrating the rate both of initiation and progression of apoptosis under 
non-cytotoxic conditions is elevated through enhanced APC activity (Figure 5.6 E, F). However, 
unlike the observed alterations in PARP cleavage, C43.4 did not provide a significant elevation in 
activity over C13.3. Combined, both approaches of measuring apoptotic activity demonstrate a 
clear trend that enhancing APC activity results in a shift toward apoptosis and cellular death, even 






Figure 5.6. Apoptotic pathways are increased upon peptide-induced APC 
activation. Qualitative representative Western blot of PARP protein cleavage from 
whole cell lysates of 231 cells A) exposed to 1.0 μM DOX for 48 hours B) exposed to 
0.5 μM DOX for 48 hours. C) 1.0 μM DOX exposure induced PARP cleavage, with 
the abundance adjusted to load control (Tubulin) and normalized to the control (231 
cell line stably transfected with an empty pcDNA vector), set to 1.00. n=3 biological 
repeats. Activity of D) Caspase 8 and E) Caspase 3 was quantified using a caspase 
activity kit (Abcam). Caspase activity is expressed as relative fluorescence unit (RFU), 
a measurement of fluorophore activity. Excitation (Ex) and emission (Em) spectra are 
expressed as Ex/Em for their respective wavelengths. n=3 technical repeats. Unpaired 
t-tests between control and individual peptides were performed to establish statistical 
significance. Error bars represent SEM, *=p<0.05. 
 
5.3.3 Enhanced APC activity induces mitotic dysregulation and genomic damage 
 A hallmark characteristic of malignant cells is dysregulation of the cell cycle, particularly 
mitosis. As mentioned previously, a dysregulated mitosis is a key promoter of cancer progression, 
inducing chromosomal mis-segregation, DNA damage, and unregulated proliferation (Crasta et 
al., 2012; Ohashi et al., 2015; Riffell et al., 2009; Zhu et al., 2014). To examine the impact of 
mitotic dysregulation upon APC activation by the peptides, we examined the change in prevalence 
of mitotic errors (mitotic catastrophes) in control 231 cells versus peptide-expressing 231 cells. 
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These are genotoxic events that occur as a result of mitotic dysregulation which would normally 
result in cell death in healthy cells and are readily visible under fluorescent microscopy after 
nuclear staining (Caruso et al., 2011). We questioned if APC activation would result in fewer 
mitotic errors due to increased apoptosis of abnormal cells even before entry into mitosis. 
However, we also acknowledged the possibility of increase mitotic errors occurring due to APC 
activity forcing grossly defective cells through mitosis, resulting in mitotic catastrophe and 
genomic damage, that may then result in enhanced sensitivity to the chemotherapeutic DOX, as it 
compounds the damage accrual.  
 Asynchronous cells were fixed to simultaneously arrest a representative MDR cell 
population at their current point in the cell cycle. Nuclei, chromosomes, and mitotic figures are 
readily visualized by fluorescent microscopy upon DAPI staining. We counted the percent of cells 
within each population residing in mitosis, as well as those experiencing a visibly abnormal mitotic 
progression/mitotic catastrophes. Although typically fatal in healthy cells, cancer cells experience 
an elevated tolerance to these defects and are frequently more prevalent in malignant populations 
(Birkbak et al., 2011; Crasta et al., 2012; Dodgson et al., 2016; Torres et al., 2010).  
 In 231 control cells (pcDNA vector without peptide-expression), we observed 2.92% of 
cells undergoing a regulated mitosis, and 3.98% experiencing a mitotic catastrophe, a relatively 
high rate but consistent with the aggressive MDR phenotype of this cancer line (Figure 5.6 B). 
The expression of either of the APC-activating peptides resulted in a significant increase in cells 
experiencing mitotic catastrophes. C13.3 elevated catastrophes by 69.1% (p<0.0001), and C43.4 
elevated catastrophes by 37.2% (p=0.0077, Figure 5.6 B). Both peptides also induced elevation in 
the number of cells imaged undergoing a regulated mitosis, although the specific implications of 
this phenomenon are unclear. The significant rise in mitotic catastrophes induced by both peptides 
indicates that enhancing APC activity leads to further dysregulation of the mitotic cycle, contrary 





Figure 5.7. Peptide-enhanced APC activity in MDR cells increased the mitotic 
catastrophe rate independent of cytotoxic or metabolic stresses. A) The percent of 
imaged cells residing in either regulated mitosis, or experiencing a mitotic catastrophe 
in an asynchronous population (combined). Unpaired t-tests established statistical 
significance between the APC-activating peptide expressing cell lines versus control 
(231 cell line stably transfected with an empty pcDNA vector); n=5 biological repeats 
error bars represent SEM. B) Asynchronous cells from (A) subdivided into those 
experiencing a regulated mitosis versus cells experiencing mitotic catastrophes. 
Unpaired t-tests established statistical significance between the peptide expressing cell 
lines and the control; n=5 biological repeats, error bars represent SEM. C) Examples 
of mitotic catastrophes captured by fluorescent microscopy. Highlighted cells include 
a tetraploid cell (failure to undergo cytokinesis, [i]), a tri-directional anaphase [ii], and 






 To explore if altered mitotic regulation resulted in the accumulation of DNA damage, we 
used phosphorylated H2A histone family member X abundance (γH2A.X, a histone variant 
recruited to sites of double strand breaks) as a quantitative marker for relative DNA damage 
accumulation. 231 cells were passaged for a month, either with or without peptide expression, 
before lysis to reach a steady state of γH2A.X accumulation in these cell populations. We observed 
that the cell population expressing APC-activating peptide C43.4 induced a significant 
accumulation of γH2A.X compared the 231 cells without APC activation, with an increase in 
γH2A.X abundance of 172% (p=0.0532) over the control (Figure 5.8). This is consistent with our 
detection of elevated rates of mitotic catastrophes, as errors in mitosis commonly contribute 
towards the accumulation of DNA damage (Crasta et al., 2012, Ohashi et al; 2015, Zhu et al., 
2014). Overall, enhancing APC activity by C43.4 increased detectable DNA damage, and would 
this contribute to chromosomal instability. C13.3 did not significantly alter γH2A.X accumulation 
(Figure 5.8). It is possible that the elevation in mitotic catastrophes observed in C13.3 are inducing 
elevated necrosis (a mechanism not observed through caspase or PARP cleavage), thereby clearing 




Figure 5.8. Dysregulated mitosis provoked by enhanced APC activity elevates 
DNA damage accumulation. A) Qualitative representative Western blot of γH2A.X 
using whole cell lysates of 231 cells passaged for one month in the presence or absence 
of APC-activating peptides. B) Quantitative representation of A) γH2A.X protein 
abundance adjusted to the Tubulin load control and normalized to the control (231 cell 
line stably transfected with an empty pcDNA vector), set to 1.00. n=3 biological 
repeats. Unpaired t-tests between control cell population and those expressing the 




5.3.4 Impact of Peptide expression on signaling pathways as measured by a Kinome Array 
 A kinome array measures the phosphorylation levels of specific phosphorylation sites on 
peptides immobilised onto an array. The phospho-peptides are often custom selected to represent 
proteins across multiple signalling pathways of particular interest. A comparison between the 
relative phosphorylation levels of two or more treatments to that of control establishes the changes 
in protein activity that occur between treatments as regulated through protein phosphorylation. Our 
array was created for another breast cancer experimental system, but a gracious donation of unused 
arrays provided us with a unique opportunity. In this case, our comparison was between 231 cells 
expressing the APC-activating peptides C13.3 and C43.4 versus empty control vector, pcDNA. 
While previous sections divided the results into C13.3 and C43.4, here we observed that the effect 
that each peptide had was similar, typically only varying in the degree of impact, and are therefore 
considered and presented together (raw data for individual peptides can be found in Appendix A.2 
and A.3 for C13.3 and C43.4 respectively).  
 Two signaling networks are described in depth due to known influences with/on APC and 
their presence of the microarray; PI3K/AKT signaling and mitogen activated protein kinase 
(MAPK). In general, peptide expression resulted in detectable alterations in protein 
phosphorylation consistent with the inhibition of both PI3K/AKT and MAPK signaling pathway. 
Importantly, both pathways promote proliferation and cell growth, while simultaneously inhibiting 
stress responses and apoptosis, such that inhibition of these pathways could enable apoptosis and 
perhaps explain the reversal of chemoresistance in these cells (Foukas et al., 2010; Kinoshita et 
al., 1997; Miller et al., 2011; Tokunaga et al., 2006; Roy et al., 2010). Also significant is the 
consistency with our previous experiments that demonstrated an elevation in stress responses and 
apoptosis upon APC-activating peptide expression.    
58 
 





Figure 5.9. AKT and MAPK Pathway alterations with elevated APC activity 
were revealed by a kinome array. Protein activity as determined by the relative 
changes in phosphorylation on known activating and inhibitory sites. 
Phosphorylation abundance changes greater than a 1.5-fold indicates a significant 
change, between 1.2 and 1.5 are considered mild changes, and phosphorylation 
changes less than 1.2-fold are considered to be no change. Proteins that 
experienced phosphorylation changes that would both promoted and impaired 
activity were considered to have mixed/no change. The mixed categorization was 
also given to proteins where one peptide promoted activity and the other impeded 
it. The greatest change observed for either peptide determined the significance 
represented. The pathway was assembled with the assistance of KEGG Pathway 
Database. A) Colorimetric representation of changes in activity are based upon 
altered phosphorylation levels only. B) Alterations in phosphorylation within the 






 To test the hypothesis that enhancement of APC activity reverses MDR behaviour through 
the restoration of two defective APC-dependent cellular mechanisms (stress response networks 
and mitotic regulation), we performed several complementary studies. Focusing first on the 
influence of APC activity on stress pathways, we were initially guided by our previous yeast 
studies that linked them together (Malo et al., 2016; Postnikoff et al., 2012). In these studies, we 
were able to demonstrate a direct pathway connecting elevated APC activity to enhanced stress 
responses through Fkh1 and Fkh2 signaling in yeast (orthologs to mammalian FOXO proteins). 
To expand this to the human model system, and to gain a more global perspective of alterations to 
the activity of the stress response networks in response to APC activity, a kinome array was 
performed which revealed altered phosphorylation levels over a broad series of interrelated stress 
and proliferation pathway proteins.  
 Significant changes to the MAPK and PI3K signaling pathways invoked by APC activation 
upon peptide expression highlight the significant role of APC in regulating stress response and 
proliferative pathways (Figure 5.9). Within each signaling pathway there are many proteins of 
known importance, and we noted that the changes influenced by APC activation/peptide 
expression were wide and impacted various signaling pathways. The kinome array therefore 
revealed specific proteins whose activities were altered in response to APC activation. As 
discussed below, we observed numerous phospho-modifications consistent with downstream 
increases/promotion of stress response signalling, with a simultaneous inhibition of proliferation 
pathway signalling. (Figure 5.9). The kinome array also identified a series of pro-oncogenic 
pathways that experienced decreased activity upon augmented APC activity. This indicates that 
enhanced APC activity serves to promote anti-tumorigenic behaviour through cellular networks, 














































Table 5.1. Altered protein abundances resulting from peptide expression. A 
summary of the observed alterations on protein accumulation resulting from C13.3 and 
C43.4 expression. 
 
 Through the observed elevated degradation of the APC substrates Cyclin A2, Cyclin B2, 
and NEK2A, we were able to establish a pathway linking enhanced APC activity with elevated 
stress responses. While both peptides provoked significant degradation of Cyclin B1 (thereby 
inhibiting CDK1, Figure 4.4 A, D), they demonstrated preference in promoting the degradation 
of Cyclin A2 and NEK2A; C43.4 supported greater degradation of Cyclin A2 (thereby inhibiting 
CDK2), whereas C13.3 induced a greater degree of NEK2A degradation (Figure 5.2). This altered 





HURP C13.3 44.4 0.0316 
4.4 
C43.4 30.7 0.0047 
Cyclin B1 C13.3 73.9 p<0.0001 
4.4 
C43.4 49.9 P<0.0001 
CDC20 C13.3 49.1 0.0702 
4.4 
C43.4 58.3 0.2372 
Cyclin A2 C13.3 70.6 0.3625 
5.2 
C43.4 105 0.4426 
NEK2A C13.3 67.3 0.1208 
5.2 
C43.4 84.7 0.4964 
p-PPP1CA T320 C13.3 65.4 0.0028 
5.3 
C43.4 68.6 0.0583 
p-AKT S473 C13.3 226 0.1535 
5.3 
C43.4 83.9 0.0749 
p-FOXO3A S253 C13.3 58.8 0.0031 
5.3 
C43.4 54.6 0.0028 
p-FOXO3A (energy 
stress) 
C13.3 39.9 0.0295 
5.4 
C43.4 43.8 0.0063 
BCRP C13.3 117 0.1108 
5.5 
C43.4 76.1 0.1824 
MDR-1 C13.3 149 0.2358 
5.5 
C43.4 82.0 0.1791 
cPARP C13.3 161 0.1062 
5.6 
C43.4 210 0.1591 
γH2A.X C13.3 110 0.2396 
5.8 
C43.4 172 0.0532 
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select for further analysis, and likely accounts for many of the discrepancies observed between 
C13.3 and C43.4 induced behaviour. This may be a more accurate model of describing the 
augmented APC activity than the broad stroke “greater elevation in activity” when discussing 
differences observed between peptide expressing cell lines (as discussed in section 4.4). 
 Based on the observed increase in PPP1 activity induced by peptide expression, we would 
expect AKT1 signaling to be impaired (Figure 5.3 A, B, C). However, this elevated PPP1 activity 
did not result in a significant downstream dephosphorylation of AKT1, as we predicted, and as has 
been previously described (Thayyullathil et al., 2011). Based on the phosphorylation of AKT 
residue S473, C43.4 provided a limited inhibition of AKT1, while C13.3 appears to have elevated 
activity. There are other key activating sites on AKT1 including Threonine308 (T308) and 
Threonine450 (T450) that may have been affected, but were not explored through western blotting 
(Sarbassov et al., 2005; Xiao et al., 2010). The kinome array contained three conserved residues 
between AKT isoforms AKT1 and AKT3 Threonine305, Threonine447, and Serine472 (conserved 
as T308, T450, and S473 respectively on AKT 1 respectively; Vasudevan and Garraway, 2010) 
which indicated an impairment to AKT3 activity (Figure 5.9 B and Appendix A.1). 
 Despite the failure to conclusively demonstrate impaired AKT1 activity based on activating 
site phosphorylation, multiple observations were made that would indicate an overall impairment 
of AKT1 activity. A key component of AKT’s oncogenic signaling is through FOXO3A inhibition 
which results in increased proliferation and cell survival (Brunet 1999). This mechanism has been 
explored for therapeutic efficacy using an approach by pharmacologically inhibiting AKT activity 
in order to promote FOXO3A transcription, and has been described in not only breast (Dey et al., 
2015), but also in pancreatic (Roy et al., 2010), leukemia (Thayyullathil et al., 2011) and colon 
cancers (Shoeb et al., 2013) demonstrating therapeutic potential for this approach. Despite the lack 
of significant AKT alterations, we observed with both C13.3 and C43.4 a marked reduction in 
inhibitory phosphorylation performed by AKT1 (Figure 5.4 A, C).  
 Another consequence of heightened AKT signaling is an induction of MDR behaviour 
through an increase in the abundance of plasma membrane drug efflux pumps that enable 
malignant cells to avoid lethal doses of chemotherapy (Goler-Baron et al., 2008; Zhou et al., 2013). 
Knowing this, we investigated the impact of peptide expression and APC activation of ABC 
transporter abundance. The observations in C43.4 cells indicates a potential reduction in both ABC 
transporter proteins tested, MDR-1 and BCRP, although the results were not sufficient to be 
considered significant (Figure 5.5). This observation supports the idea of C43.4 inhibiting AKT 
signalling, as AKT activity promotes ABC transporter accumulation (Goler-Baron et al., 2008, 
Zhou et al., 2013). The restoration of chemosensitivity occurred most potently with the C43.4 
peptide, and given that apoptotic signaling was equal between the two peptides under non-
cytotoxic condition, but elevated to a greater extent in C43.4 upon DOX exposure (Figure 5.6), 
the reduced presence of ABC transport proteins possibly contributed to this phenomenon.  
 The impact of increasing APC activity through peptide expression was also observed by 
the elevated responsiveness of 231 cells to metabolic stresses, namely a nutrient/energy stress 
arising from growth in limited glucose media; the increases in FOXO3A activity induced by APC 
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activity was augmented by nutrient and energy stress. Specifically, FOXO3A was more active in 
low glucose, as compared to high glucose, media (Figure 5.3 A, D and Figure 5.4). This 
adaptation of stress pathway activity indicates an elevated capability of the cells to respond to not 
only the cytotoxic stress of DNA damaging agents such as the chemotherapy DOX, but also to 
retain robust responses to the stresses of energy deprivation. This is relevant to one of the hallmarks 
of cancer development, the Warburg Effect where cancer cells ramp up a modified energy 
metabolism shifted towards glycolysis and lactic acid synthesis, and away from oxidative 
phosphorylation (Hanahan and Weinberg, 2011; Vander Heiden et al., 2017). This energy-depleted 
state should induce AMPK activation and signalling (anti-oncogenic), and a simultaneous 
suppression of nutrient signalling through mTORC activity (pro-oncogenic) and AKT, to prevent 
proliferation and induce stress responses. This shift in metabolism is thought to be reinforced by 
the hypoxic environment of tumors (DeBardainis et al., 2008). This is relevant when considering 
the interplay between proliferative and stress response circuitry response to stressful stimuli as a 
therapeutic route, and the impact APC activity may therefore have. For instance, caloric restriction 
and caloric restriction mimetics (rapamycin and metformin) have demonstrated themselves to be 
promising adjunct therapies to improve clinical cancer outcomes (Meynet and Ricci, 2014).  
 Expression of two APC-activating peptides appears to shift signalling pathways in our 
MDR cell line in a way that apoptosis is restored and chemosensitivity is enhanced. In 2001, it 
was demonstrated that restoring apoptotic pathways, by inducing Caspase 3 overexpression, was 
an effective method to overcome/reverse MDR behaviour (Friedrich at al., 2001). Caspase 
activity, central to the apoptotic pathways, is commonly found to be impaired in human tumors as 
a means of avoiding apoptosis (Olsson and Zhivotovsky, 2011). Anti-stress responses, particularly 
AKT-dependent activities, are capable of both directly impairing caspase activity through direct 
inhibition of caspase proteins, as well as altering the regulation of BCL-2 family proteins to inhibit 
apoptosis (Datta et al., 1997; Gardai et al., 2004; Fernald and Kurokawa, 2013). C43.4, which 
provoked the greater elevation in apoptosis as measured by PARP cleavage (Figure 5.6 A-D), also 
induced the greater elevation in sensitivity to chemotherapy (Figure 4.5) as compared to peptide 
C13.3. This supports our conclusion that the elevated cell death observed upon peptide expression 
is likely a result of enhanced apoptotic pathways. The elevated apoptotic rates observed in response 
to DOX exposure was not proportional to the FOXO3A elevation, therefore it is likely that multiple 
mechanisms are simultaneously promoting sensitivity to DOX, including MDR transporter 
abundances, as mentioned previously. Another potential mechanism that may be induced by 
peptide expression, but not explored here, would be the presence of necrosis induction in response 
to chemotherapy. Our data therefore supports our secondary hypothesis, that enhancing APC 
activity reverses MDR behaviour through restoration of defective cellular mechanisms. 
 Mitotic errors and DNA damage accumulation were the second key APC function 
investigated in our MDR model, in order to determine the impact of APC activity on cancer 
behavior. We observed that for both peptides, elevating APC activity resulted in a significantly 
increased rate of dysregulation in mitosis. We found clear evidence that enhancing APC activity 
in 231 cells dramatically increased the frequency of mitotic catastrophes even in the absence of 
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cytotoxic chemotherapy (Figure 5.6). This contradicts our hypothesis stating that enhancing APC 
activity will restore cellular processes to normal, and instead highlighted the possibility of an 
unknown and alternative pathway whereby normalized APC activity can result in enhanced 
‘endogenous’ cancer cell death rates, and ultimately improve treatment responses to therapy.  
 A clue to the underlying cellular mechanism causing this enhanced mitotic catastrophe 
comes from the reported in vitro effects of two commercial APC activators, Mad2 inhibitors (M2I-
1) and TTK kinase inhibitors (TTKi). It remains to be determined how the peptides may actually 
influence APC activity, but the end result appears to be mechanistically similar to that observed 
with these commercial activators. Both M2I-1 and TTKi treatments have been demonstrated in 
vitro to promote a dysregulated mitosis that induces catastrophic genomic damage and results in 
malignant cell death as monotherapy, under high doses (Li 2019, Maia 2018, Wenger 2016). 
However, the in vitro combination of M2I-1 and TTKi have demonstrated synergistic anti-
tumorigenic affects with chemotherapy agents (Li 2019, Maia 2018, Wenger 2016), again 
producing a result similar to our in vitro studies using peptides C43.4 and C13.3. and DOX (Figure 
4.5).  
 A mechanistic explanation for the altered MDR behaviour upon APC activation should 
consider the possibility that activation of cell cycle checkpoints (specifically the SAC in this 
instance) may slow down the cell cycle and replication, enabling the partial repair of defects 
occurred during mitosis. It has been reported that cancer cells with impaired APC activity 
experience reduced chromosomal instability (Sansregret et al., 2017). This reduced chromosomal 
instability and may function similarly to that observed with restoration of BRCA1 and BRCA2 
activity. Here, there is partial repair of the genome, thereby preventing the cell death induced by 
chemotherapy (Husain et al., 1998; Sakai et al., 2008). By enhancing APC activity and inducing 
mitotic catastrophes, the burden of elevated chromosomal instability may act to promote cell death 
(Birkbak et al., 2011). This may occur through both APCCDC20 and APCCDH1, as despite CDC20 
experiencing enhanced degradation upon peptide expression (Figure 4.4 A, C), the enhanced 
degradation of NEK2A also indicates that APCCDC20 is also specifically elevated, as NEK2A 
degradation is exclusively driven by CDC20. As mentioned in Section 4.4, it appears that CDH1-
dependent APC activity is clearly elevated, as noted by the degradation of CDC20 (by both 
peptides), which is exclusively driven by CDH1. Therefore, it is also possible that CDH1 is 
inducing the mitotic dysregulation through promoting mitotic slippage (Nagai et al., 2014; Toda 
et al., 2012; Park et al., 2018).  
 The peptides also were noted to modestly increase the number of cells within a population 
residing in mitosis, and there are multiple possible interpretations for this (Figure 5.6 B). The first 
could be that enhancing APC activity encourages cells to enter mitosis, possibly in a dysregulated 
manner. An accelerated cell cycle implies bypassing cell cycle checkpoints, potentially 
overcoming MDR behaviour induced through checkpoint activation (Harrington et al., 1994; 
Ferrao et al., 2012; Morgan et al., 2010). The second interpretation is that APC activity slows the 
process of mitosis, meaning more cells exist in mitosis at any given time. This is frequently seen 
in various mutant S. cerevisiae strains, where the proportion of cells rises greatly to reside 
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preferentially in one stage of the cell cycle. 231 cells expressing peptides exhibited a modest 
increase in mitotic figures per population would indicate a more regulated mitosis is occurring, as 
mitotic checkpoint activation is arresting mitosis. However, this is contradictory to published 
observations using M2I-1 to activate the APC in vitro. Here, impaired SAC activity reduced the 
time in mitosis (Kastl 2015). One consequence of an excessively long mitotic arrest is accrual of 
DNA damage and potentially mitotic catastrophe (Bonaiuti et al., 2018, Dalton et al., 2007; 
Quignon et al., 2007). The former interpretation of promoting cell cycle progression better fits the 
current data, however further investigation is essential to clarify/elucidate the underlying 
mechanisms resulting in our observed impacts on mitosis upon APC activation in MDR cells. 
 It is also important to discuss the increased rates of DNA damage upon APC activation 
with peptides, in cells simultaneously exhibiting mitotic dysregulation (Figure 5.7). Again, this 
was counterintuitive to our hypothesis, where we posited that DNA damage would in fact be 
decreased due to enhanced repair rates. We considered how this observation might relate to the 
enhanced chemosensitivity found upon peptide expression. Clearly, the induction of (catastrophic) 
DNA damage through pharmacological agents has long been a staple of cancer chemotherapy, 
including the general drug classes of alkylating (cisplatin)s and anthracycline (DOX) agents, for 
example. Therefore, it is possible that the elevated DNA damage induced through enhanced APC 
activity pushes the cancer population closer to irreparable genomic damage, and makes the cells 
more susceptible to DNA damaging agents (Birkbak et al., 2011). C13.3 however was unable to 
induce an elevation in γH2A.X accumulation. The cause of this phenomenon is unknown, however 
one potential explanation is that C13.3 induces more catastrophic accumulation of DNA damage 
than C43.4 and is more likely to induce cell death through necrosis (a mechanism we have not 
characterized) even without the addition of the chemotherapeutic agent.  
 Several clear differences in our endpoints were found between the C13.3. and C43.4 
peptides, however this was not further examined in our experiments. There are many explanations 
for the different outcomes between them, including the fact that the peptides were initially 
identified in yeast through binding to different APC subunits (Table 4.1). In the yeast 2-hybrid 
library, peptide C13.3 bound to the APC5 subunit (important for APC structural integrity and E3 
activity) and C43.4 bound the APC10 subunit (essential for substrate recognition). Importantly, 
we have not yet confirmed that either peptide expressed in 231 cells is directly binding the human 
APC, but could also have unique off-target interactions that may influence APC activity and 
cellular pathways to reverse MDR behaviors. This may drive differential activation of cellular 
pathways to enhance unique cellular pathway activity depending on the peptide used. Overall, the 
behavioural changes demonstrated by the elevated stress response pathways, apoptosis, MDR 
reversal, and kinome array indicate that the APC overall acts as a tumor suppressor protein. This 
corresponds with the known functions of the APC in healthy cells, including protecting the genome 





Chapter 6. Conclusion 
 
 This thesis investigated two hypotheses. Our primary hypothesis was supported by our 
investigations and demonstrated that enhancement of APC activity results in reversal of MDR 
behaviour in cancer and restoration of chemosensitivity. Our investigation utilized novel peptides 
identified in a yeast 2-hybrid library as being capable of directly binding APC subunits and 
enhancing yeast APC activity. We adapted the peptides to be endogenously expressed in the 
innately MDR cancer line MDA-MB-231. This resulted in two peptides, C13.3 and C43.4, being 
confirmed as being capable of enhancing APC activity. This elevated APC activity coincided with 
a significantly elevated sensitivity to the chemotherapeutic DOX. Our secondary hypothesis 
addressed the possibility that the targeted enhancement of APC activity would correct defects that 
promote MDR behaviour, including normalised mitotic progression, and decreases in DNA 
damage accumulation. In support of our secondary hypothesis, we did reveal evidence that stress 
responses and apoptosis was increased upon peptide expression and APC activation in the MDR 
cell model. We were able to construct a cellular pathway connecting the observed degradation of 
multiple APC protein substrates relevant to the stress response networks and altered signalling 
within the networks themselves. Notably, we detected marked changes in the phosphorylation of 
PPP1. This is indicative of elevated PPP1 activity, promoting the dephosphorylation of protein 
targets to repress cell proliferation, and enhance apoptosis and repair. 
 Our results when investigating the next step in the pathway, AKT1 were mixed. We noted 
a mild decrease in AKT activity with C43.4, and an elevation with C13.3. However, we observed 
multiple alterations to cellular behaviour indicative of a net impairment of AKT activity with both 
peptides. The most important observation was the promotion FOXO3A activity, indicating the 
induction of stress response pathways. We did observe that peptide expression markedly reduced 
the inhibitory phosphorylation of FOXO3A performed by AKT1. This occurred under both rich 
and nutrient/energy limiting conditions, with a subsequent elevation in several apoptotic markers 
both endogenously and also when exposed to the chemotherapy agent DOX. Together, this suggest 
that by enhancing APC activity, we are restoring defective apoptotic pathways. As revealed by the 
kinome array, enhancing APC activity also broadly as induced extensive alterations to protein 
phosphorylation of multiple stress response proteins. In both the MAPK and PI3K pathways these 
changes broadly indicate the activation of stress responses while simultaneously suppressing 
proliferation.  
 Contrary to our secondary hypothesis, the enhancement of APC activity resulted in 
increased rates of mitotic dysregulation. This likely acted to enhance the sensitivity of the MDR 
cancer cells to the therapeutic and cytotoxic effects of chemotherapy, as a dysregulated mitosis is 
one of the key mechanisms through which cancer cells accrue DNA damage. This elevated DNA 
damage may synergize with DOX (which functions through inducing DNA damage), to induce 
cell death. Therefore, the activity of the APC is intrinsically tied to the presence of MDR 




Chapter 7. Future Directions 
 
 This adaptation of APC-activating peptides for human expression and investigation into 
MDR behavior was limited in scope, as it was performed exclusively in MDA-MB-231 cells, and 
it is therefore difficult to draw conclusions regarding the applicability of this research to other 
cancer types. Therefore, replication of these studies should be performed in a second 
complementary in vitro model. One excellent candidate would be to use paired cancer cell lines 
that are matched except for chemosensitivity. Our lab is well positioned to generate acquired 
chemoresistance cell lines to study MDR behaviour, rather than innately MDR observed in the 231 
cells, as we have previously generated such paired lines in human leukemia, lymphoma, and 
estrogen receptor positive breast caner cells. This would not only verify the impact of elevating 
APC activity in a secondary cell line, but may yield data on the mechanisms at play in cells 
undergoing an MDR transformation. The ability to induce a MDR phenotype is also a unique 
opportunity to determine if APC activation can in fact prevent drug resistance from developing. 
This is clinically relevant when considering patients who have excellent initial responses to their 
chemotherapy, but return years later with MDR. It may be that a role for chronic low-level APC 
stimulation could be clinically significant in preventing these untreatable recurrences. The data 
presented were also exclusively in vitro, and are therefore missing crucial data on the impact that 
these peptides have in an in vivo model. To study an in vivo model, peptide expressing 231 cells 
would be implanted into immunocompromised mice to develop solid tumors. These tumors could 
then be evaluated for several measures of cancer behaviour. This would include the impact on 
tumor growth, and responsiveness to chemotherapy. These in vitro studies are currently underway 
by Gabrielle Mercier and Dr. Gerald Davies.    
 Currently we have little understanding of how the peptides of interest function to drive 
APC activity. The most important aspect of peptide behaviour to demonstrate would be whether 
they are biologically functional due to direct APC interactions, indirect effects due to unique off-
target associations, or a combination of both. Direct associations between the peptides and the 
human APC complex could be addressed by several means. Co-immunoprecipitation assays would 
confirm peptide binding to the APC protein complex, as co-immunoprecipitation would pulldown 
the entire E3 with all bound accessory proteins; however, the information potentially obtained 
about peptide binding is limited due to the entire complex being retrieved when a single subunit is 
targeted so that the interacting subunit would not be necessarily identified. Another binding assay 
that has the advantage of highlighting protein proximity to the peptide of interest would be BioID, 
where the peptides are fused to a mutated biotin ligase that promiscuously tags nearby proteins. 
These tagged proteins can then be purified through biotin affinity purification, and then identified 
through mass spectrophotometry. BioID would provide an interaction map of the peptide, as well 
as potentially identify nearby proteins that associate with the APC, therefore also identifying 
potential off-target interactions that are biologically relevant. Proteins located closer to peptides 
would produce a stronger signal in the screen, thereby helping to identify a more specific binding 
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location. Based on known regulatory measures, this may identify the mechanisms by which the 
peptides enhance APC activity.  
 Further investigation of impact of these peptides on cell cycle regulation is warranted. The 
elevated mitotic catastrophes indicate that there is a loss of mitotic regulation that occurs from 
enhanced APC activity; however, the underlying mechanisms are not understood. This would 
involve several experiments. First, observation of the cell cycle following synchronization. This 
will indicate if the peptides alter the cell cycle, with respect to the timing of the different sections 
of interphase, and the impact of enhanced APC activity on cell cycle checkpoints. Most 
importantly, this will establish the impact of APC activation on mitotic timing. Are regulatory 
mechanisms being activated or impaired by enhanced APC activity? These experiments would be 
repeated from multiple points of the cell cycle to gain a thorough picture of cell cycle regulation. 
A second experiment will focus specifically on mitotic regulation. We could examine the impact 
of APC activation on the induction of mitotic slippage by using chemical inhibitors of mitotic 
progression. The question being asked is do peptide expressing cells experience exaggerated 
mitotic arrest, or do they experience slippage at an elevated rate when compared to control? This 
would elaborate on the mechanisms that drive mitotic regulation, and verify our current data 
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A.1 Alterations to Pathway Activity Identified in the Kinome Array 
 
MAPK signaling Pathway: The mitogen-activated protein kinase (MAPK) pathway contains 
many oncogenes commonly found to be overexpressed, or experience gain-of function mutations 
in cancer. Activation of the APC generated a downregulation of the pathway. Two principle 
initiators of the MAPK pathway are the receptor tyrosine kinases (RTKs) EGFR and Kit. Active 
EGFR and Kit phosphorylate SHC1, a linker protein which forms protein complexes to transduce 
the signal from RTKs to induce the MAPK signaling pathways. A key function of SHC1 is the 
binding of the guanine nucleotide exchange factor (GEF) SOS1 to facilitate its activation by 
localizing it to the RTKs. SOS1 would then promote the activity of the Ras family of proteins 
including Rac1 and HRas, through exchanging bound GDP (inactive state) for GTP (active state). 
Downstream of Rac1 and HRas are BRAF and RAF1. BRAF and RAF1 are directly 
phosphorylated by HRas. An alternative method of activating MAP3K proteins is through the PAK 
proteins, whose activity can be induced by either JAK/STAT signaling or Rac1. Both RAF1 and 
BRAF phosphorylate MEK1/2 to promote their activity, which in turn activates ERK2. 
 
 EGFR, Kit, and SHC1 experienced a decrease in activity, impairing pathway activation. 
By inhibiting SOS1, Rac1 and HRas are inhibited through elevated GDP binding (although this is 
not examined by the kinome array. Rac1 and HRAS also experienced a loss of activity through 
altered phosphorylation levels. BRAF found to have a loss of activity while RAF1 had elevated 
activity. The elevation in RAF1 activity is likely through activation of the JAK/STAT pathway. 
The gain in JAK signalling compensates for the loss of Rac1 and HRas activity through driving 
PAK1 activity. This is demonstrated in the loss of phosphorylation of Rac1 targeted residues and 
the gain in phosphorylation JAK1 targeted residues. PAK1 then phosphorylates RAF1, driving its 
activity and activating the MEK1. MEK2 was not significantly altered to either enhance, or inhibit 
activity. ERK2 was found to have a decrease in activity however, despite the elevation in MEK1 
activity. This is likely from elevated DUSP1 activity which dephosphorylates ERK family proteins 
to inhibit their activity. Examination of EKR2 substrates verified the loss of activity ERK2, as 
FOS, JUN, and MSK1 experienced a loss of activity. Ribosomal protein S6 kinase (RPS6) alpha-
3 (RPS6KA3) activity was slightly enhanced, potentially acting as a stop signal for MAPK 




 PI3K: The PI3K pathway had conflicting signaling pathways. Insulin receptor (IRS) 
signaling was elevated, therefore driving activity of the PI3K family. PI3K isoforms B and D were 
found to have upregulated activity, but isoform G experienced decreased activity. Simultaneously 
PTEN was upregulated. The net result of these conflicting pathways is decreased signaling 
downstream of PIP3 as indicated by the critical loss of the critical activating autophosphorylation 
of 3-phosphoinositide-dependent protein kinase-1 (PDK1), which is phosphorylated upon 
interaction with PIP3. There were both mild elevations to mTOR activyt, as well as one significant 
inhibitory event, resulting in the net impact on mTOR activity being mixed. The loss of PDK1 
activity corresponded with a reduction in the activity of PDK1 substrates within the AKT and PKC 
protein families. The effects of the altered PKC signaling is demonstrated in the moderate 
downregulation of Protein Kinase D1 (PRKD1) activity which acts as intermediary for may of the 
PKC family proteins in promoting their pathways. 
  
 AKT: AKT exists as 3 isoforms, AKT1, 2, and 3. Activating proteins of the AKT family, 
PKD1, Heat Shock Protein 90 Beta Family Member 1 (HSP90B1), mTOR, and PKCA were all 
found to be downregulated in activity. Overall effect of this altered phosphorylation pattern 
indicates an overall decrease in activity of AKT isoforms. AKT 3 was the best characterized 
protein in the array and was found to be downregulated through loss of multiple activating 
phosphorylation sites. Only one AKT1 site (T450) was present in the final data set, and 
demonstrated moderate dephosphorylation. Due to conservation between isoforms, 
dephosphorylation of AKT 3 is likely to indicate dephosphorylation of AKT1. Examination of the 
AKT phosphorylation sites on Raf-1, Glycogen Synthase Kinase 3 Alpha (GSK3α), SMAD3 
revealed a loss of phosphorylation at sites performed by AKT proteins, indicating a reduction in 
AKT activity. CDK1 and CDK2, while not directly phosphorylated by AKT, experience activity 
promotion through upstream AKT activity. The loss of AKT signaling correlated with a loss in 
CDK1 and CDK2 activity.   
  
 MTORC1: Given the mixed alteration to mTOR, the distinct complexes may experience 
separate alterations to activity. Regulatory-associated protein of TOR 1 (RAPTOR) experienced 
a decrease in activation, indicating that MTORC1 activity is likely impaired. Two substrates of 
MTORC1 experienced altered phosphorylation indicating MTORC1 inhibition, EIF4BP1 
(eukaryotic initiation factor 4 [EIF4] binding protein) and RPS6KB1. EIF4BP1 is a negative 
allosteric inhibitor of EIF4. By preventing EIF4 activity, elevated EIF4BP1 is reducing global 
protein synthesis as EIF4 binds mRNA to induce protein translation. RPS6KB1 induces multiple 
events to promote proliferation prevent apoptosis and experienced a decrease in activity.  
   
 TGFβ: Transforming growth factor beta (TGFβ) receptor 1 (TGFBR1) experienced a loss 
of activating phosphorylation. Despite this, SMAD 1 and 2, substrates of TGFBR1 kinase activity 
experienced an elevation in phosphorylation to promote activity. Bone morphogenetic protein 
receptors (BMPRs) were not included in the final data set, however an upregulation of their activity 
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would promote SMAD2 phosphorylation (but not SMAD1), and therefore activity. SMAD 3 
experienced a loss of inhibitory phosphorylation from AKT1 and multiple CDKs, notable from the 
observed loss of CDK2. The SMAD proteins would then be free to dimerize in the nucleus to 
transcribe proteins in an anti-tumorigenic manner. 
 
 NFκB: Nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) signalling 
is initiated through activity of inhibitor of nuclear factor kappa-B kinase (IKK) proteins. The 
signaling was mixed as IKKα experienced an elevation in activity, while IKKε experienced a 
decrease in activity. There are multiple proteins not characterized in the kinome array that may 
explain the upregulation of IKKα activity (the IKKα sites phosphorylated by AKT1 were not 
characterized by the array). IKKε activity is primarily driven by EGFR, and the reduction in EGFR 
activity explains this loss of activity. IKK proteins induce NFκB signalling through 
phosphorylation of NFκB 1 and NFκB Inhibitor alpha (NFKBIA; an inhibitory chaperone of 
NFκB). The phosphorylation of NFκB 1 and 2 promotes their activity, and the phosphorylation of 
NFKBIA promotes its degradation. NFKBIA experienced a loss of these phosphorylation events. 
Phosphorylation of NFκB 1 indicated an increase in activity, however the impact on transcriptional 
activity is not certain as NFKBIA is still abundant and may be downregulating NFKIBA activity 
through allosteric regulation. NFκB2 experienced a direct decrease in activity through 
phosphorylation. Due to the complicated transcriptional networking involving NFκB 1 
dimerization with multiple transcriptional factors not included in the array, a solid conclusion on 
the overall outcome of the altered NFκB activity would only be speculative. The main conclusion 
to be reached is that NFκB 2 signaling be downregulated upon APC activation. 
 
 JAK/STAT: The JAK/ STAT signaling pathways are promoted by an elevated abundance 
of Interferon alpha/beta receptor 1 (INFAR1), as indicated by a decrease in the phosphorylation 
site that promotes degradation. INFAR1 is then capable of promoting the activity of JAK proteins. 
Suppressor of cytokine signaling 3 (SOCS3) allosterically regulates JAK activity by binding 
phosphorylated JAK proteins (in a negative-feedback pathway), and exhibited elevated activity. 
The upregulation of SOCS3 activity does not appear to be sufficient to completely suppress JAK 
signaling, as while STAT 1 and 3 both experience a decrease in activating phosphorylation induced 
by JAKs, as mentioned previously, PAK 1 experienced a mild increase in activating 
phosphorylation from JAK1.  
 
 Apoptosis: 14-3-3ζ binds and inhibits activity of Bcl2-associated agonist of cell death 
(BAD), which promotes apoptosis through inhibition of the anti-apoptotic proteins B-cell 
lymphoma 2 (BCL-2) and BCL extra large (Bcl-xL). The elevated phosphorylation of 14-3-3ζ 
results in its dissociation from BAD, to permit apoptosis. The activity of MAPKPK2 and the kinase 
function of Bcr and were both elevated to perform these inhibitory events. This would permit BAD 
activity to permit initiation of mitotic pathways. Caspase 3 activity was also elevated through 
phosphorylation events. This is in part due to the reduction in P38A activity, which inhibits 
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Caspase 3 activity. Many of the above discussed pathways may either promote or impede 






A.2 Kinome Data for C13.3 
 
             Negative predictive value up  
        Negative predictive value down 
ID Accession      Sequence  FC  P up P down Beta up Beta down  
P42345 S2449 RSRTRTDSYSAGQSV 1.28010  0.00997 0.99003 0.11432 0.99992 0.07501 0.65613 
P42345 S2482 TVPESIHSFIGDGLV 1.26664  0.05801 0.94199 0.14155 0.99986 0.09288 0.65610 
P42345 S1261 PMKKLHVSTINLQKA -1.59115 0.99926 0.00074 1.00000 0.00008 0.65619 0.00005 
Q8N122 S863 LTQSAPASPTNKGIH -1.40957 0.99299 0.00701 1.00000 0.00787 0.65619 0.00517 
Q13131 S486 DEITEAKSGTATPQR 1.20467  0.06319 0.93681 0.25727 0.99935 0.16882 0.65576 
P35568 S1095 GCRRRHSSETFSSTP -1.35057 0.98164 0.01836 1.00000 0.00488 0.65619 0.00320 
P48736 S582 LWHFRYESLKDPKAY -1.87502 0.99964 0.00036 1.00000 0.00091 0.65619 0.00059 
P42338 Y505 ENKKQPYYYPPFDKI 1.27398  0.01073 0.98927 0.07851 0.99997 0.05152 0.65616 
P42338 Y963 RVPFILTYDFIHVIQ -1.24520 0.90407 0.09593 0.99943 0.24472 0.65582 0.16058 
P42338 S1071 KVNWMAHTVRKDYRS -1.98467 0.99692 0.00308 1.00000 0.00854 0.65619 0.00560 
O00329 S1021 KVNWLAHNVSKDNRQ -1.90299 1.00000 0.00000 1.00000 0.00000 0.65619 0.00000 
O00329 Y524 RRGSGELYEHEKDLV -1.22603 0.96069 0.03931 0.99998 0.06233 0.65617 0.04090 
P00533 Y1172 PAAENAEYLRAAPAG -1.88178 1.00000 0.00000 1.00000 0.00000 0.65619 0.00000 
P00533 Y1067 TFLPVPEYVNQSVPK 1.34304  0.00568 0.99432 0.00223 1.00000 0.00146 0.65619 
P00533 Y846 LGAEEKEYHAEGGKV 1.20403  0.09046 0.90954 0.28746 0.99911 0.18863 0.65560 
Q15831 S309 SASSKIRRLSACKQQ -1.32964 0.98186 0.01814 0.99999 0.04213 0.65618 0.02765 
P60484 S346 EPDHYRYSDTTDSDP -1.63533 0.99341 0.00659 1.00000 0.00085 0.65619 0.00055 
P60484 Y104 TGVMICAYLLHRGKF -1.87008 0.99997 0.00003 1.00000 0.00000 0.65619 0.00000 
O15530 Y374 SEDDEDCYGNYDNLL 1.42421  0.00138 0.99862 0.00015 1.00000 0.00010 0.65619 
P17252 T401 MDGVTTRTFCGTPDY 1.28839  0.01934 0.98066 0.09675 0.99994 0.06349 0.65615 
P17252 T542 TRGQPVLTPPDQLVI -1.82660 0.99977 0.00023 1.00000 0.00029 0.65619 0.00019 
Q02156 S368 NNIRKALSFDNRGEE 1.51688  0.00003 0.99997 0.00001 1.00000 0.00001 0.65619 
Q02156 S729 QEEFKGFSYFGEDLM -1.22567 0.94313 0.05687 0.99967 0.20012 0.65597 0.13131 
Q02156 T566 LNGVTTTTFCGTPDY -1.48242 0.99553 0.00447 1.00000 0.00931 0.65619 0.00611 
Q04759 S695 QNMFRNFSFMNPGME -1.65764 0.99889 0.00111 1.00000 0.00027 0.65619 0.00018 
Q04759 T538 LGDARTNTFCGTPDY -1.85084 1.00000 0.00000 1.00000 0.00000 0.65619 0.00000 
Q04759 Y90 SETTVELYSLAERCR -2.98488 1.00000 0.00000 1.00000 0.00000 0.65619 0.00000 
Q9Y243 S472 RPHFPQFSYSASGRE -1.37883 0.95837 0.04163 0.99997 0.07125 0.65617 0.04676 
Q9Y243 S120 EEERMNCSPTSQIDN -1.25256 0.98009 0.01991 0.99995 0.09195 0.65615 0.06034 
Q9Y243 T305 TDAATMKTFCGTPEY -1.79159 0.99171 0.00829 1.00000 0.00081 0.65619 0.00053 
P14625 T165 ELVKNLGTIAKSGTS -1.71514 0.99937 0.00063 1.00000 0.00000 0.65619 0.00000 
P14625 S347 KPIWQRPSKEVEEDE -1.71943 0.98701 0.01299 1.00000 0.02129 0.65619 0.01397 
P23443 T252 HDGTVTHTFCGTIEY -1.74163 0.99239 0.00761 1.00000 0.00111 0.65619 0.00073 
P23443 S394 TRQTPVDSPDDSALS -1.89912 0.99996 0.00004 1.00000 0.00000 0.65619 0.00000 
P23443 T412 NQVFLGFTYVAPSVL 1.21896  0.08511 0.91489 0.25379 0.99937 0.16653 0.65578 
Q13541 S65 FLMECRNSPVTKTPP -2.12796 1.00000 0.00000 1.00000 0.00000 0.65619 0.00000 
Q13541 T46 GGTLFSTTPGGTRII -2.70795 1.00000 0.00000 1.00000 0.00000 0.65619 0.00000 
Q99558 T558 TGDYIPGTETHMAPE -1.13988 0.90370 0.09630 0.99820 0.36432 0.65500 0.23906 
O15111 S181 DQGSLCTSFVGTLQY 1.75679  0.00000 1.00000 0.00000 1.00000 0.00000 0.65619 
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Q14164 S666 RTQGAQASPPLTAPY 1.14349  0.03148 0.96852 0.28515 0.99913 0.18711 0.65562 
Q14164 S172 DDDEKFVSVYGTEEY -1.63766 0.99995 0.00005 1.00000 0.00000 0.65619 0.00000 
P25963 T291 EDEESYDTESEFTED -2.63998 0.99350 0.00650 1.00000 0.00148 0.65619 0.00097 
P68400 Y182 DWGLAEFYHPGQEYN 1.67131  0.00760 0.99240 0.00541 1.00000 0.00355 0.65619 
P19838 S337 FVQLRRKSDLETSEP 1.64253  0.00017 0.99983 0.00000 1.00000 0.00000 0.65619 
P19838 S928 RDDSICDSGVETSFR 1.32069  0.00217 0.99783 0.00242 1.00000 0.00159 0.65619 
Q00653 S99 EVDLVTHSDPPRAHA -1.68338 1.00000 0.00000 1.00000 0.00000 0.65619 0.00000 
Q00653 S708 EPLCPLPSPPTSGSD 1.66975  0.00000 1.00000 0.00000 1.00000 0.00000 0.65619 
P06493 T161 GIPIRVYTHEVVTLW 1.58714  0.00068 0.99932 0.00020 1.00000 0.00013 0.65619 
P24941 Y15 EKIGEGTYGVVYKAR 1.22562  0.04224 0.95776 0.21759 0.99959 0.14278 0.65592 
P24941 S46 TETEGVPSTAIREIS 1.62183  0.00019 0.99981 0.00006 1.00000 0.00004 0.65619 
P36897 T189 LPLLVQRTIARTIVL -2.08400 0.99989 0.00011 1.00000 0.00000 0.65619 0.00000 
Q15797 S187 NSHPFPHSPNSSYPN 1.46335  0.00172 0.99828 0.00452 1.00000 0.00297 0.65619 
P84022 T133 PQSNIPETPPPGYLS -1.23898 0.97638 0.02362 0.99994 0.09740 0.65615 0.06391 
P17612 T201 RVKGRTWTLCGTPEY -1.44732 0.99835 0.00165 1.00000 0.00564 0.65619 0.00370 
P17612 S339 EEEEIRVSINEKCGK -1.88453 0.99999 0.00001 1.00000 0.00000 0.65619 0.00000 
P10721 Y569 EEINGNNYVYIDPTQ -1.51782 0.99669 0.00331 0.99999 0.03726 0.65618 0.02445 
P29353 Y427 ELFDDPSYVNVQNLD -2.04367 0.99831 0.00169 1.00000 0.00380 0.65619 0.00249 
P29353 S36 TPPEELPSPSASSLG -2.01144 0.98321 0.01679 0.99999 0.04955 0.65618 0.03252 
Q07889 T158 NIRHYEITKQDIKVA -1.72955 0.99987 0.00013 1.00000 0.00000 0.65619 0.00000 
P01112 T144 YGIPYIETSAKTRQG 1.49119  0.00001 0.99999 0.00008 1.00000 0.00005 0.65619 
P01112 S183 DEGGPGCLSCRCLLS 1.41273  0.00745 0.99255 0.03439 0.99999 0.02257 0.65618 
P01112 T35 FVDEYDPTIEDSYRK -1.39837 0.99702 0.00298 1.00000 0.00931 0.65619 0.00611 
P46940 T1392 DKMKKSKTIKEDSSL -1.62356 0.99989 0.00011 1.00000 0.00014 0.65619 0.00009 
P46940 Y1459 LVKLQQTYAALNSKA -2.54355 1.00000 0.00000 1.00000 0.00000 0.65619 0.00000 
P46940 S282 ALFKILQSPALGLRG 1.52307  0.00339 0.99661 0.00810 1.00000 0.00531 0.65619 
P04049 S43 FGYQRRASDDGKLTD -1.16740 0.91150 0.08850 0.99926 0.26925 0.65570 0.17668 
P04049 S259 SQRQRSTSTPNVHMV -1.28330 0.95881 0.04119 0.99995 0.09375 0.65615 0.06152 
P17181 S536 SSQTSQDSGNYSNED -1.55506 0.99969 0.00031 1.00000 0.00000 0.65619 0.00000 
P17181 Y467 VFLRCVKYVFFPSSK 1.22233  0.01298 0.98702 0.09488 0.99995 0.06226 0.65615 
P23458 Y1033 AIETDKEYYTVKDDR 3.66103  0.00000 1.00000 0.00000 1.00000 0.00000 0.65619 
P23458 T686 HRKSDVLTTPWKFKV 1.88660  0.00400 0.99600 0.00085 1.00000 0.00055 0.65619 
P42224 Y1114 DGPKGTGYIKTELIS -1.25932 0.93669 0.06331 0.99971 0.19087 0.65600 0.12525 
P40763 Y705 DPGSAAPYLKTKFIC -1.48899 0.94198 0.05802 0.99973 0.18403 0.65601 0.12076 
Q13153 Y284 QGASGTVYTAMDVAT 1.36492  0.00030 0.99970 0.02722 1.00000 0.01786 0.65618 
Q13153 S198 PRPEHTKSVYTRSVI -1.44372 0.92871 0.07129 0.99975 0.17998 0.65602 0.11810 
O96013 S475 KEVPRRKSLVGTPYW -1.45048 0.99015 0.00985 0.99995 0.09051 0.65616 0.05939 
Q02750 T388 IGLNQPSTPTHAAGV -1.44418 0.99990 0.00010 1.00000 0.00828 0.65619 0.00544 
Q02750 S222 VSGQLIDSMANSFVG 1.51665  0.00101 0.99899 0.01442 1.00000 0.00946 0.65619 
Q02750 S298 RTPGRPLSSYGMDSR -1.22344 0.93124 0.06876 0.99964 0.20653 0.65595 0.13552 
P36507 T398 TLRLNQPSTPTRTAV -1.27576 0.93278 0.06722 0.99988 0.13271 0.65611 0.08708 
P36507 S306 RPPGRPISGHGMDSR -1.29790 0.99952 0.00048 0.99999 0.04382 0.65618 0.02875 
P28482 T141 ADPDHDHTGFLTEYV 1.36111  0.00033 0.99967 0.00289 1.00000 0.00190 0.65619 
P28482 Y187 HTGFLTEYVATRWYR -1.56030 0.99363 0.00637 1.00000 0.00982 0.65619 0.00644 
P51812 S386 HQLFRGFSFVAITSD 1.82719  0.00018 0.99982 0.00000 1.00000 0.00000 0.65619 
P51812 S369 TAKTPKDSPGIPPSA -1.52814 0.97591 0.02409 1.00000 0.02387 0.65618 0.01566 
Q15418 S380 HQLFRGFSFVATGLM -1.27279 0.97243 0.02757 0.99995 0.09627 0.65615 0.06317 
P05412 Y170 LHSEPPVYANLSNFN -1.83530 0.99999 0.00001 1.00000 0.00000 0.65619 0.00000 
P05412 S63 KNSDLLTSPDVGLLK 1.36981  0.01465 0.98535 0.02451 1.00000 0.01609 0.65618 
Q16539 Y323 DEPVADPYDQSFESR -1.43241 0.99290 0.00710 1.00000 0.00740 0.65619 0.00485 
P49137 T322 QSTKVPQTPLHTSRV 1.61202  0.00007 0.99993 0.00000 1.00000 0.00000 0.65619 
P49137 T209 TSHNSLTTPCYTPYY 2.03403  0.00009 0.99991 0.00000 1.00000 0.00000 0.65619 
P49137 S259 SNHGLAISPGMKSRI 1.81316  0.00034 0.99966 0.00026 1.00000 0.00017 0.65619 
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P42574 S150 FRGDYCRSLTGKPKL -1.83092 0.99999 0.00001 1.00000 0.00000 0.65619 0.00000 
P63104 S58 VVGARRSSWRVVSSI 1.61168  0.00000 1.00000 0.00000 1.00000 0.00000 0.65619 
P63104 T110 LTLWTSDTQGDEAEA 1.49460  0.00347 0.99653 0.00718 1.00000 0.00471 0.65619 
P11274 S120 GLPYIDDSPASSPHL -1.33993 0.98753 0.01247 1.00000 0.02008 0.65619 0.01318 
P11274 Y21 VSPSPTTYRPFRDKS 2.96232  0.00000 1.00000 0.00000 1.00000 0.00000 0.65619 
Q05655 S645 LNEKPRLSYSDKNLI -1.35829 0.98638 0.01362 0.99999 0.04386 0.65618 0.02878 
Q15139 S642 ARIIGEKSFRRSVVG 1.21350  0.02857 0.97143 0.06906 0.99997 0.04532 0.65617 
Q15139 Y367 NDTGSRYYKEIPLSE -1.43859 0.95949 0.04051 1.00000 0.02800 0.65618 0.01838 
P31749 T442 TAQMITITPPDQDDS -1.45421 0.98102 0.01898 0.99999 0.04000 0.65618 0.02624 
P49840 S39 GGGGPGGSASGPGGS -1.36291 0.99787 0.00213 1.00000 0.01157 0.65619 0.00759 
P49840 S39 GGGGPGGSASGPGGS -1.36291 0.99787 0.00213 1.00000 0.01157 0.65619 0.00759 
P49840 S21 SGRARTSSFAEPGGG -1.40496 0.97646 0.02354 0.99999 0.04593 0.65618 0.03014 
P15056 T104 IGDFGLATVKSRWSG -1.69026 0.98866 0.01134 1.00000 0.00262 0.65619 0.00172 
P15056 S339 GQRDRSSSAPNVHIN -1.27608 0.91781 0.08219 0.99850 0.34324 0.65520 0.22523 
O14543 Y208 VNGHLDSYEKVTQLP -2.07321 0.99980 0.00020 1.00000 0.00000 0.65619 0.00000 
O14543 Y225 PGPIREFLDQYDAPL 1.54126  0.04149 0.95851 0.08069 0.99996 0.05295 0.65616 
P01100 S362 AAAHRKGSSSNEPSS -1.46756 0.96721 0.03279 0.99994 0.09822 0.65615 0.06445 
P01100 T232 GGLPEAATPESEEAF -1.67349 0.99962 0.00038 1.00000 0.00004 0.65619 0.00003 
 
A.3 Kinome Data for C43.4 
  
               Negative predictive value down 
ID Accession   FC  P up P down Beta up Beta down Negative predictive value up  
P42345 S1261 -1.29592 0.97134 0.02866 1.00000 0.03183 0.64186 0.02043 
Q8N122 S863 -1.63799 0.99948 0.00052 1.00000 0.00031 0.64187 0.00020 
Q13131 S486 1.12863  0.03060 0.96940 0.33261 0.99863 0.21349 0.64099 
P35568 S1095 -1.75880 0.99995 0.00005 1.00000 0.00000 0.64187 0.00000 
P35568 S312 1.33513  0.00419 0.99581 0.02092 1.00000 0.01343 0.64186 
P48736 T607 -1.43568 0.93958 0.06042 0.99971 0.19130 0.64168 0.12279 
P48736 S582 -1.65658 0.99505 0.00495 1.00000 0.01262 0.64186 0.00810 
P42338 Y505 1.19539  0.02685 0.97315 0.23052 0.99952 0.14796 0.64156 
P42338 Y963 -1.30925 0.94124 0.05876 0.99993 0.10729 0.64182 0.06886 
P42338 S1071 -1.57462 0.97933 0.02067 0.99992 0.11231 0.64181 0.07209 
O00329 S1021 -1.79495 1.00000 0.00000 1.00000 0.00000 0.64187 0.00000 
P00533 Y846 1.34666  0.00395 0.99605 0.07506 0.99997 0.04818 0.64185 
P00533 Y1172 -1.83275 0.99622 0.00378 1.00000 0.00019 0.64187 0.00012 
Q15831 S309 -1.45061 0.99660 0.00340 1.00000 0.00752 0.64186 0.00483 
Q15831 S183 1.54843  0.00858 0.99142 0.00869 1.00000 0.00558 0.64186 
P60484 S346 -1.47335 0.98569 0.01431 1.00000 0.00684 0.64186 0.00439 
P60484 Y104 -1.59003 0.99850 0.00150 1.00000 0.00039 0.64187 0.00025 
O15530 S242 -2.10767 1.00000 0.00000 1.00000 0.00000 0.64187 0.00000 
O15530 Y374 1.48158  0.01912 0.98088 0.04558 0.99999 0.02926 0.64186 
P17252 Y562 1.60337  0.00003 0.99997 0.00006 1.00000 0.00004 0.64187 
P17252 T401 1.65075  0.00306 0.99694 0.01102 1.00000 0.00707 0.64186 
Q02156 S368 2.00517  0.00001 0.99999 0.00000 1.00000 0.00000 0.64187 
Q04759 T538 -1.23781 0.97086 0.02914 0.99998 0.05481 0.64186 0.03518 
Q04759 S695 -1.65632 0.98804 0.01196 1.00000 0.00355 0.64187 0.00228 
Q04759 Y90 -1.65532 0.99897 0.00103 1.00000 0.00017 0.64187 0.00011 
Q9Y243 S120 -1.56940 0.99969 0.00031 1.00000 0.00130 0.64187 0.00083 
Q9Y243 S472 -1.28061 0.95348 0.04652 0.99974 0.18358 0.64170 0.11783 
Q9Y243 T447 -1.34746 0.96580 0.03420 0.99927 0.26801 0.64140 0.17203 
Q9Y243 T305 -1.59213 0.99110 0.00890 1.00000 0.00222 0.64187 0.00142 
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P14625 S347 -1.86881 0.99152 0.00848 1.00000 0.00870 0.64186 0.00559 
P14625 T165 -3.20505 1.00000 0.00000 1.00000 0.00000 0.64187 0.00000 
P23443 S394 -1.92465 1.00000 0.00000 1.00000 0.00000 0.64187 0.00000 
P23443 T412 1.27522  0.02321 0.97679 0.09876 0.99994 0.06339 0.64183 
Q13541 S101 -1.42447 0.98688 0.01312 0.99997 0.07800 0.64184 0.05007 
Q13541 S65 -1.44205 0.99909 0.00091 1.00000 0.00394 0.64187 0.00253 
Q13541 T46 -2.03422 1.00000 0.00000 1.00000 0.00000 0.64187 0.00000 
Q99558 T558 -1.21100 0.94038 0.05962 0.99978 0.17237 0.64172 0.11064 
O15111 S181 1.33433  0.00063 0.99937 0.13662 0.99987 0.08769 0.64178 
Q14164 S666 -1.14878 0.95298 0.04702 0.99943 0.24502 0.64150 0.15727 
Q14164 S172 -1.63503 0.99999 0.00001 1.00000 0.00012 0.64187 0.00008 
P25963 S283 1.89164  0.00019 0.99981 0.00000 1.00000 0.00000 0.64187 
P25963 T291 -2.76633 0.99516 0.00484 1.00000 0.00051 0.64187 0.00033 
P68400 Y182 1.85201  0.00100 0.99900 0.00082 1.00000 0.00052 0.64187 
P19838 S905 -1.22148 0.90069 0.09931 0.99954 0.22604 0.64157 0.14509 
P19838 S337 2.60878  0.00000 1.00000 0.00000 1.00000 0.00000 0.64187 
P19838 S928 1.74371  0.00000 1.00000 0.00000 1.00000 0.00000 0.64187 
Q00653 S708 1.16606  0.01783 0.98217 0.19025 0.99971 0.12212 0.64168 
Q00653 S99 -1.22519 0.99288 0.00712 0.99995 0.09561 0.64183 0.06137 
P06493 T161 1.43621  0.00262 0.99738 0.00082 1.00000 0.00053 0.64187 
P24941 S46 1.39858  0.00647 0.99353 0.00723 1.00000 0.00464 0.64186 
P24941 Y15 1.28540  0.04064 0.95936 0.15563 0.99983 0.09989 0.64175 
P24941 T160 1.28857  0.09519 0.90481 0.24510 0.99943 0.15732 0.64150 
P36897 T189 -1.91374 0.99989 0.00011 1.00000 0.00001 0.64187 0.00001 
Q15797 S187 1.48976  0.00303 0.99697 0.02657 1.00000 0.01705 0.64186 
Q15797 S532 1.22464  0.05781 0.94219 0.15086 0.99984 0.09683 0.64176 
Q15797 S206 1.17086  0.09275 0.90725 0.54279 0.99298 0.34840 0.63736 
Q15796 S467 1.50434  0.01579 0.98421 0.08191 0.99996 0.05257 0.64184 
P84022 T133 -1.23550 0.92689 0.07311 0.99922 0.27400 0.64137 0.17587 
P17612 T201 -1.39747 0.99643 0.00357 1.00000 0.01288 0.64186 0.00827 
P17612 S339 -1.53132 0.99984 0.00016 1.00000 0.00018 0.64187 0.00011 
P10721 Y569 -2.00115 0.99991 0.00009 1.00000 0.00002 0.64187 0.00001 
P10721 Y937 -1.46164 0.99994 0.00006 1.00000 0.00023 0.64187 0.00015 
P10721 Y722 -1.17023 0.95349 0.04651 0.99937 0.25474 0.64146 0.16351 
P29353 S36 -1.84108 0.96881 0.03119 0.99995 0.09569 0.64183 0.06142 
P29353 Y427 -2.42152 0.99896 0.00104 1.00000 0.00173 0.64187 0.00111 
Q07889 S1134 1.52478  0.00821 0.99179 0.01449 1.00000 0.00930 0.64186 
Q07889 S1197 1.39768  0.02461 0.97539 0.08617 0.99996 0.05531 0.64184 
Q07889 T158 -1.49110 0.99019 0.00981 1.00000 0.00290 0.64187 0.00186 
P01112 T35 -1.80295 0.99597 0.00403 1.00000 0.00784 0.64186 0.00503 
P01112 T144 1.32245  0.00329 0.99671 0.05520 0.99998 0.03543 0.64185 
P01112 S183 1.28485  0.00861 0.99139 0.10525 0.99993 0.06756 0.64182 
P46940 S282 1.16688  0.07235 0.92765 0.27250 0.99924 0.17491 0.64137 
P46940 T1392 -1.74884 0.99999 0.00001 1.00000 0.00000 0.64187 0.00000 
P46940 Y1459 -2.89224 1.00000 0.00000 1.00000 0.00000 0.64187 0.00000 
P63000 T96 2.27267  0.00000 1.00000 0.00000 1.00000 0.00000 0.64187 
P04049 S338 1.62717  0.00207 0.99793 0.10856 0.99993 0.06968 0.64182 
P04049 S43 -1.20012 0.95459 0.04541 0.99985 0.14585 0.64177 0.09362 
P04049 S259 -1.32716 0.99691 0.00309 1.00000 0.01211 0.64186 0.00777 
P17181 S536 -2.04312 1.00000 0.00000 1.00000 0.00000 0.64187 0.00000 
P17181 Y482 1.42979  0.00043 0.99957 0.00595 1.00000 0.00382 0.64186 
P17181 Y467 1.23497  0.01793 0.98207 0.10514 0.99993 0.06749 0.64182 
P23458 T686 2.15356  0.00000 1.00000 0.00000 1.00000 0.00000 0.64187 
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P23458 Y1033 4.44389  0.00000 1.00000 0.00000 1.00000 0.00000 0.64187 
P42224 Y1114 -2.28319 0.99999 0.00001 1.00000 0.00000 0.64187 0.00000 
P40763 S727 1.30038  0.01276 0.98724 0.04129 0.99999 0.02650 0.64186 
Q13153 S198 -1.92179 0.99634 0.00366 1.00000 0.00272 0.64187 0.00174 
Q13153 Y284 1.54170  0.00009 0.99991 0.00446 1.00000 0.00286 0.64187 
Q13177 S141 -1.09723 0.93999 0.06001 0.99893 0.30599 0.64118 0.19640 
O96013 S475 -1.41050 0.99272 0.00728 0.99998 0.05527 0.64185 0.03548 
O96013 S181 1.31202  0.00126 0.99874 0.01841 1.00000 0.01182 0.64186 
O96013 S99 1.25986  0.03162 0.96838 0.23029 0.99952 0.14781 0.64156 
Q02750 S222 1.92785  0.00007 0.99993 0.00003 1.00000 0.00002 0.64187 
P36507 S306 1.38031  0.00190 0.99810 0.02270 1.00000 0.01457 0.64186 
P36507 S226 1.29689  0.00806 0.99194 0.01679 1.00000 0.01078 0.64186 
P36507 T398 -1.32680 0.99289 0.00711 1.00000 0.01509 0.64186 0.00969 
P28482 S246 -1.76240 0.99537 0.00463 1.00000 0.00173 0.64187 0.00111 
P28482 Y187 -1.25596 0.90398 0.09602 0.99924 0.27178 0.64138 0.17445 
P51812 S386 1.93158  0.00087 0.99913 0.00031 1.00000 0.00020 0.64187 
Q15418 T359 1.48848  0.00043 0.99957 0.00034 1.00000 0.00022 0.64187 
P05412 Y170 -1.16658 0.96480 0.03520 0.99757 0.40039 0.64030 0.25700 
Q16539 Y323 -1.52622 0.99346 0.00654 1.00000 0.00102 0.64187 0.00066 
Q16539 Y182 -1.32150 0.95991 0.04009 0.99981 0.16003 0.64175 0.10272 
P49137 T322 1.69502  0.00001 0.99999 0.00000 1.00000 0.00000 0.64187 
P49137 S259 2.45711  0.00005 0.99995 0.00000 1.00000 0.00000 0.64187 
P49137 T209 1.38802  0.07592 0.92408 0.24664 0.99942 0.15831 0.64149 
P42574 S150 -2.36038 1.00000 0.00000 1.00000 0.00000 0.64187 0.00000 
P63104 S58 1.26221  0.00052 0.99948 0.00320 1.00000 0.00206 0.64187 
P63104 T110 1.90184  0.00397 0.99603 0.00350 1.00000 0.00225 0.64187 
P11274 S120 -1.59722 0.99936 0.00064 1.00000 0.00023 0.64187 0.00015 
P11274 Y21 4.30017  0.00000 1.00000 0.00000 1.00000 0.00000 0.64187 
 
A.4 Phenol Chloroform DNA Purification from E. coli 
 
1. Grow cultures in LBA overnight at 37oC with agitation 
2. Centrifuge media at 10,000 rpm, discard supernatant 
3. Resuspend pellet in glucose-Tris-EDTA buffer (50 mM glucose, 25 mM Tris-HCl pH 
8.0, 10 mM EDTA) and incubate for 5 min at RT 
4. Add lysis buffer to a final concentration of 0.13 M NaOH, 0.66% SDS then incubate for 
5 min on ice 
5. Add NaAc pH 4.8 to a final concentration of 1 M and incubate for 5 min on ice 
6. Centrifuge at 18,000 rpm and 4oC for 5 min 
7. Decant supernatant and add 1:2 v/v isopropanol:supernatant 
8. Incubate on ice for 5 min then centrifuge at 18,000 rpm and 4oC for 5 min 
9. Discard supernatant and resuspend pellet in 2:1 v/v 6.6 M LiCl:phenol-chloroform 
10. Vortex and incubate at RT for 5 min 
11. Centrifuge at 14,800 rpm for 2 min and extract aqueous layer 
12. Add 3X 95% Ethanol (EtOH) and incubate at -80oC for 30 min 
13. Centrifuge at 18,000 rpm and 4oC for 5 min then discard supernatant 
14. Add 70% ice cold EtOH and centrifuge 18,000 rpm and 4oC for 5 min 
15. Discard supernatant then resuspend pellet in 1X TE buffer (10 mM Tris-HCl pH 8.0, 1 




A.5 Gel Extraction Purification 
 
1. Run endonuclease reaction on a 1.5% low melt agarose gel  
2. Excised fragments from the gel and combine with 2.5X volume 50 mM NaCl  
3. Incubate at 65oC for up to 10 min with intermittent vortexing  
4. Mix gel/NaCl solution 1:1 v/v with phenol  
5. Vortex then centrifuged at 14,800 rpm for 2 min.  
6. Decant supernatant  
7. Repeat steps 4-6 until no interface remains.  
8. Mix supernatant 1:1 v/v with n-butanol, vortex, and centrifuge at 14,800 rpm for 2 min 
9. Extract the aqueous layer and mix with 3X 95% EtOH then incubate at -80oC for 30 min 
10. Centrifuge at 18, 000 rpm and 4oC for 10 min. 
11. Decant supernatant and resuspend DNA in 1X TE 
